1. Gurney JG, Smith MA, Bunin GR. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. NIH Pub No 99-4649. Bethesda, MD: National Cancer Institute, SEER Program, 1999:51–63.
2. Gurney JG, Wall DA, Jukich PJ, et al. The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States. Cancer Causes Control 1999;10:101–105.
3. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. 1997;80:2321–2323.
4. Bleyer WA. Epidemiologic impact of children with brain tumors. Childs Nerv Syst 1999;15:758–763.
5. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.
6. Ries LA, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973–1994. NIH Pub No 97-2789. Bethesda, MD: National Cancer Institute, SEER Program, 1997.
7. Smith MA, Freidlin B, Ries LA, et al. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 1998;90:1269–1277.
8. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91:1382–1390.
9. Bunin G. What causes childhood brain tumors? Limited knowledge, many clues. Pediatr Neurosurg 2000;32:321–326.
10. Preston-Martin S. Epidemiology of primary CNS neoplasms. Neurol Clin 1996;14:273–290.
11. Kleihues P. World Health Organization classification of tumours. In: Kleihaus P, Cauance WK, eds. Pathology and genetics of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer Press, 2000:208–241.
12. Evans G, Burnell L, Campbell R, et al. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 1993;21:433–434.
13. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 1997;76:141–145.
14. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997;69:299–308.
15. Eberhart CG. Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli. Am J Pathol 2003;162:7–10.
16. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992;69:111–117.
17. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841–851.
18. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668–1671.
19. Amlashi SF, Riffaud L, Brassier G, et al. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003;98:618–624.
20. Taylor MD, Mainprize TG, Rutka JT. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000;47:888–901.
21. Foulkes WD. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 1995;88:853–863
22. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot’s syndrome. N Engl J Med 1995;332:839–847.
23. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233–1238.
24. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348:747–749.
25. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193–201.
26. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181–186.
27. Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999;89:38–44.
28. Pollack IF, Mulvihill JJ. Neurofibromatosis 1 and 2. Brain Pathol 1997;7:823–836.
29. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800.
30. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515–521.
31. Kandt RS, Haines JL, Smith M, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet 1992;2:37–41.
32. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805–808.
33. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64–67.
34. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317–1320.
35. Duan DR, Humphrey JS, Chen DY, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A 1995;92:6459–6463.
36. Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444–1446.
37. Ron E, Modan B, Boice JD Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033–1039.
38. Kimball D V, Gelber RD, Li F, et al. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:2848–2853.
39. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95:2770–2775.
40. Rimm IJ, Li FC, Tarbell NJ, et al. Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13-year experience from the Dana-Farber Cancer Institute and the Children’s Hospital. Cancer 1987;59:1506–1508.
41. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330–1336.
42. Bader JL, Meadows AT, Zimmerman LE, et al. Bilateral retinoblastoma with ectopic intracranial retinoblastoma: trilateral retinoblastoma. Cancer Genet Cytogenet 1982;5:203–213.
43. Savla J, Chen TT, Schneider NR, et al. Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors. J Natl Cancer Inst 2000;92:648–650.
44. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835–853.
45. Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res 1995; 55:5991–6001.
46. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998;2:56–63.
47. Gold EB, Leviton A, Lopez R, et al. The role of family history in risk of childhood brain tumors. Cancer 1994;73:1302–1311.
48. Draper GJ, Heaf MM, Kinnier Wilson LM. Occurrence of childhood cancers among sibs and estimation of familial risks. J Med Genet 1977;14:81–90.
49. Kuijten RR, Bunin GR. Risk factors for childhood brain tumors. Cancer Epidemiol Biomarkers Prev 1993;2:277–288.
50. Farwell J, Flannery JT. Cancer in relatives of children with central-nervous-system neoplasms. N Engl J Med 1984;311:749–753.
51. Kuijten RR, Strom SS, Rorke LB, et al. Family history of cancer and seizures in young children with brain tumors: a report from the Children’s Cancer Group (United States and Canada). Cancer Causes Control 1993;4:455–464.
52. Taylor MD, Gokgoz N, Andrulis IL, et al. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet 2000;66:1403–1406.
53. Proust F, Laquerriere A, Constantin B, et al. Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings. J Neurooncol 1999;43:63–70.
54. Moschovi M, Sotiris Y, Prodromou N, et al. Familial medulloblastoma. Pediatr Hematol Oncol 1998;15:421–424.
55. Zwetsloot CP, Kros JM, Gueze HD. Familial occurrence of tumours of the choroid plexus. J Med Genet 1991;28:492–494.
56. Fitzgerald LF. Familial brainstem glioma. Clin Neurol Neurosurg 2000;102:106–108.
57. Dirven CM, Tuerlings J, Molenaar WM, et al. Glioblastoma multiforme in four siblings: a cytogenetic and molecular genetic study. J Neurooncol 1995;24:251–258.
58. Norman MA, Holly EA, Ahn DK, et al. Prenatal exposure to tobacco smoke and childhood brain tumors: results from the United States West Coast childhood brain tumor study. Cancer Epidemiol Biomarkers Prev 1996;5:127–133.
59. Robison LL, Buckley JD, Bunin G. Assessment of environmental and genetic factors in the etiology of childhood cancers: the Children’s Cancer Group epidemiology program. Environ Health Perpect 1995;103[Suppl 6]:111–116.
60. Ali Kahn A, O’Brien DF, Kelly P, et al. The anatomical distribution of cerebral gliomas in mobile phone users. Ir Med J 2003;96:240–242.
61. Hardell L, Mild KH, Carlberg M. Case-control study on the use of cellular and cordless phones and the risk for malignant brain tumours. Int J Radiat Biol 2002;78:931–936.
62. Hardell L, Mild KH, Carlberg M. Further aspects on cellular and cordless telephones and brain tumours. Int J Oncol 2003;22:399–407.
63. Hansson Mild K, Hardell L, Kundi M, et al. Mobile telephones and cancer: is there really no evidence of an association? (review). Int J Mol Med 2003;12:67–72.
64. Kundi M, Mild K, Hardell L, et al. Mobile telephones and cancer—a review of epidemiological evidence. J Toxicol Environ Health B Crit Rev 2004;7:351–384.
65. Khalili K, Del Valle L, Otte J, et al. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003;22:5181–5191.
66. Fine HA. Polyomavirus and medulloblastoma: a smoking gun or guilt by association? J Natl Cancer Inst 2002;94:240–241.
67. Hayashi H, Endo S, Suzuki S, et al. JC virus large T protein transforms rodent cells but is not involved in human medulloblastoma. Neuropathology 2001;21:129–137.
68. Kim JY, Koralnik IJ, LeFave M, et al. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro-oncology 2002;4:165–170.
69. Bigner SH, Bjerkvig R, Laerum OD. DNA content and chromosomal composition of malignant human gliomas. Neurol Clin 1985;3:769–784.
70. Mark SJ, Laerum OD. Modal DNA content of human intracranial neoplasms studied by flow cytometry. J Neurosurg 1980;53:198–204.
71. Christov K, Zapryanov Z. Flow cytometry in brain tumors. I. Ploidy abnormalities. Neoplasma 1986;33:49–55.
72. Giangaspero F, Burger PC. Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme. A postmortem study of 50 cases. Cancer 1983;52: 2320–2333.
73. Shapiro JR, Mehta BM, Fiola MR. Intrinsically chemo- and radioresistant subpopulations identified in freshly resected human gliomas become the dominant population in recurrent tumor samples. Neurology 1990;40:395.
74. Raffel C, Gilles FE, Weinberg KI. Reduction to homozygosity and gene amplification in central nervous system primitive neuroectodermal tumors of childhood. Cancer Res 1990;50:587–591.
75. Douglass EC, Look AT, Kun LE. Cellular DNA content is predictive of early relapse in medulloblastoma. Pediatr Neurosci 1990;15:140.
76. Yasue M, Tomita T, Engelhard H, et al. Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 1989;70:385–391.
77. Biegel JA, Burk CD, Barr FG, et al. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992;52:3391–3395.
78. Thomas GA, Raffel C. Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors. Cancer Res 1991;51:639–643.
79. Bigner SH, Mark J, Friedman HS, et al. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 1988;30:91–101.
80. Griffin CA, Hawkins AL, Packer RJ, et al. Chromosome abnormalities in pediatric brain tumors. Cancer Res 1988;48:175–180.
81. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085–2088.
82. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842–845.
83. Xie J, Johnson RL, Zhang X, et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 1997;57:2369–2372.
84. Dong J, Gailani MR, Pomeroy SL, et al. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat 2000;16:89–90.
85. Reardon DA, Michalkiewicz E, Boyett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997;57: 4042–4047.
86. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74–79.
87. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986;322:644–647.
88. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203–206.
89. Schnitzler G, Sif S, Kingston RE. Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state. Cell 1998;94:17–27.
90. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosome Cancer 1999;24:230–237.
91. Kramer DL, Parmiter AH, Rorke LB, et al. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998;37:25–33.
92. Lang FF, Miller DC, Koslow M, et al. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427–436.
93. Coons SW, Johnson PC, Shapiro JR. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res 1995;55:1569–1577.
94. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304–309.
95. James CD, He J, Carlbom E, et al. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res 1991;51: 1684–1688.
96. Fults D, Pedone CA, Thomas GA, et al. Allelotype of human malignant astrocytoma. Cancer Res 1990;50:5784–5789.
97. Wasson JC, Saylors RL III, Zeltzer P, et al. Oncogene amplification in pediatric brain tumors. Cancer Res 1990;50:2987–2990.
98. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324–1330.
99. Litofsky NS, Hinton D, Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994;34:967–972.
100. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39–45.
101. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755–764.
102. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786–1792.
103. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res 2001;61:7404–7407.
104. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346:420–427.
105. Zulch K. Brain tumors: their biology and pathology, 3rd ed. Berlin: Springer-Verlag, 1986.
106. Kernonhan JW, Mabon RF, Svien HJ, et al. Pro Staff Meet May. Clinic 1949, 71–75.
107. Daumas-Duport C, Scheithauer B, O’Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152–2165.
108. Kleihues P, Burger PC, Scheihauer B, et al. Histological typing of tumors of the central nervous system. Berlin: Springer-Verlag, 1993.
109. Rorke LB, Gilles FH, Davis RL, et al. Revision of the World Health Organization classification of brain tumors for childhood brain tumors. Cancer 1985;56:1869–1886.
110. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986;314: 1423–1431.
111. Kobayashi H. The biological modification of tumor cells as a means of inducing their regression: an overview. J Biol Response Mod 1986;5:1–11.
112. Gould VE. Histogenesis and differentiation: a re-evaluation of these concepts as criteria for the classification of tumors. Hum Pathol 1986;17:212–215.
113. Clark HB. Immunohistochemistry of nervous system antigens: diagnostic applications in surgical neuropathology. Semin Diagn Pathol 1984;1:309–316.
114. Coakham HB, Brownell B. Monoclonal antibodies in the diagnosis of cerebral tumors and cerebrospinal fluid neoplasia. In: Cavanaugh JB, ed. Recent advances in neuropathology. Edinburgh, Churchill Livingstone, 1986:25–53.
115. Perentes E, Rubinstein LJ. Recent applications of immunoperoxidase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 1987;111:796–812.
116. Gould VE, Jansson DS, Molenaar WM, et al. Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest 1990;62:498–509.
117. Molenaar WM, Jansson DS, Gould VE, et al. Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors. Lab Invest 1989;61:635–643.
118. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996;85:56–65.
119. Bender BL, Yunis EJ. Central nervous system pathology of tuberous sclerosis in children. Ultrastruct Pathol 1980;1:287–299.
120. Nakamura Y, Becker LE. Subependymal giant-cell tumor: astrocytic or neuronal? Acta Neuropathol (Berl) 1983;60:271–277.
121. Bonnin JM, Rubinstein LJ, Papasozomenos SC, et al. Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study. Acta Neuropathol (Berl) 1984;62:185–193.
122. Powell SZ, Yachnis AT, Rorke LB, et al. Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. Am J Surg Pathol 1996;20:80–85.
123. Perry A, Giannini C, Scheithauer BW, et al. Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. Am J Surg Pathol 1997;21:763–771.
124. Taratuto AL, Monges J, Lylyk P, et al. Superficial cerebral astrocytoma attached to dura. Report of six cases in infants. Cancer 1984;54:2505–2512.
125. VandenBerg SR, May EE, Rubinstein LJ, et al. Desmoplastic supratentorial neuroepithelial tumors of infancy with divergent differentiation potential (“desmoplastic infantile gangliogliomas”). Report on 11 cases of a distinctive embryonal tumor with favorable prognosis. J Neurosurg 1987;66:58–71.
126. Taratuto AL, VandenBerg SR, Rorke LB. Desmoplastic infantile astrocytoma and ganglioglioma. Lyon, France: International Agency for Research on Cancer Press, 2000.
127. Hassoun J, Gambarelli D, Grisoli F, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol (Berl) 1982;56:151–156.
128. Bailey P, Cushing H. Medulloblastoma cerebelli: a common type of cerebellar glioma of childhood. Arch Neurol Psychiatry 1925;14:192–225.
129. Cushing H. Experiences with the cerebellar medulloblastoma: a critical review. Acta Pathol Microbiol Scand 1930;7:1–86.
130. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1–15.
131. Hart MN, Earle KM. Primitive neuroectodermal tumors of the brain in children. Cancer 1973;32:890–897.
132. Kershman J. The medulloblast and medulloblastoma. A study of human embryos. Arch Neurol Psychiat 1938;40:937–967.
133. Fujita S. Quantitative analysis of cell proliferation and differentiation in the cortex of the postnatal mouse cerebellum. J Cell Biol 1967;32:277–287.
134. Fujita S, Shimada M, Nakamura T. H3-thymidine autoradiographic studies on the cell proliferation and differentiation in the external and the internal granular layers of the mouse cerebellum. J Comp Neurol 1966;128:191–208.
135. Swarz JR, Del Cerro M. Lack of evidence for glial cells originating from the external granular layer in mouse cerebellum. J Neurocytol 1977;6:241–250.
136. Fulop Z, Lakos I, Basco E, et al. Identification of early glial elements as the precursors of Bergmann-glia: a Golgi-analysis of the developing rat cerebellar cortex. Acta Morphol Acad Sci Hung 1979;27:273–280.
137. Ghandour MS, Labourdette G, Vincendon G, et al. A biochemical and immunohistological study of S100 protein in developing rat cerebellum. Dev Neurosci 1981;4:98–109.
138. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999;22:103–114.
139. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15–28.
140. Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 2003;13:34–42.
141. Marino S, Vooijs M, van Der Gulden H, et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994–1004.
142. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436–442.
143. Pomeroy SL, Sturla LM. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg 2003;39:299–304.
144. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257–282.
145. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306–310.
146. Aldosari N, Rasheed BK, McLendon RE, et al. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathol (Berl) 2000;99:345–351.
147. Rorke L, Hart M, McLendon RE. Supratentorial primitive neuroectodermal tumor (PNET). Lyon, France: IARC Press, 2000.
148. Shapira E, Marom K, Yelin R, et al. A role for the homeobox gene Xvex-1 as part of the BMP-4 ventral signaling pathway. Mech Dev 1999;86:99–111.
149. Tarabykin V, Britanova O, Fradkov A, et al. Expression of PTTG and prc1 genes during telencephalic neurogenesis. Mech Dev 2000;92:301–304.
150. Boquet I, Hitier R, Dumas M, et al. Central brain postembryonic development in Drosophila: implication of genes expressed at the interhemispheric junction. J Neurobiol 2000;42:33–48.
151. Ho KS, Scott MP. Sonic hedgehog in the nervous system: functions, modifications and mechanisms. Curr Opin Neurobiol 2002;12:57–63.
152. Schuurmans C, Guillemot F. Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol 2002;12:26–34.
153. Rubenstien J, Puelles L. Development of the nervous system. New York: Oxford University Press, 2004.
154. Rorke LB. Pathology of brain and spinal cord tumors. In: Chous M DC, Hockley AD, et al., eds. Pediatric neurosurgery. London: Churchill Livingstone, 1999.
155. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–748.
156. Yachnis AT, Trojanowski JQ. Studies of childhood brain tumors using immunohistochemistry and microwave technology: methodological considerations. J Neurosci Methods 1994;55:191–200.
157. Honig PJ, Charney EB. Children with brain tumor headaches. Distinguishing features. Am J Dis Child 1982;136:121–124.
158. Barlow CF. Headaches and brain tumors. Am J Dis Child 1982;136:99–100.
159. Glaser JS, Hoyt WF, Corbett J. Visual morbidity with chiasmal glioma. Long-term studies of visual fields in untreated and irradiated cases. Arch Ophthalmol 1971;85:3–12.
160. Albright AL, Sclabassi RJ, Slamovits TL, et al. Spasmus nutans associated with optic gliomas in infants. J Pediatr 1984;105:778–780.
161. Yang PJ, Berger PE, Cohen ME, et al. Computed tomography and childhood seizure disorders. Neurology 1979;29:1084–1088.
162. Rich KM, Goldring S, Gado M. Computed tomography in chronic seizure disorder caused by glioma. Arch Neurol 1985;42:26–27.
163. Rasmussen T. Surgical aspects of temporal lobe epilepsy. Results and problems. Acta Neurochir Suppl (Wien) 1980;30:13–24.
164. Spencer DD, Spencer SS, Mattson RH, et al. Intracerebral masses in patients with intractable partial epilepsy. Neurology 1984;34:432–436.
165. Smith KR Jr., Weinburg WA, McAlister WH. Failure to thrive: the diencephalic syndrome of infancy and childhood. J Neurosurg 1965;23:348–351.
166. Torrey EF, Uyeda CI. The diencephalic syndrome of infancy: report of two cases. Am J Dis Child 1965;110:689–696.
167. Packer RJ, Siegel KR, Sutton LN, et al. Leptomeningeal dissemination of primary central nervous system tumors of childhood. Ann Neurol 1985;18:217–221.
168. Rodriguez LA, Edwards MS, Levin VA. Management of hypothalamic gliomas in children: an analysis of 33 cases. Neurosurgery 1990;26:242–246.
169. Fisher PG, Jenab J, Goldthwaite PT, et al. Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv Syst 1998;14:558–563.
170. Sklar CA. Craniopharyngioma: endocrine abnormalities at presentation. Pediatr Neurosurg 1994;21[Suppl 1]:18–20.
171. Packer RJ, Sutton LN, Rosenstock JG, et al. Pineal region tumors of childhood. Pediatrics 1984;74:97–102.
172. Sanford RA, Freeman CR, Burger P, et al. Prognostic criteria for experimental protocols in pediatric brainstem gliomas. Surg Neurol 1988;30:276–280.
173. Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 2000;89:1569–1576.
174. Gol A, McKissock W. The cerebellar astrocytomas: a report on 98 verified cases. J Neurosurg 1959;16:287–296.
175. Zec N, Cera P, Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery 1991;29:34–37.
176. Mercuri S, Russo A, Palma L. Hemispheric supratentorial astrocytomas in children. Long-term results in 29 cases. J Neurosurg 1981;55:170–173.
177. Palma L, Guidetti B. Cystic pilocytic astrocytomas of the cerebral hemispheres. Surgical experience with 51 cases and long-term results. J Neurosurg 1985;62:811–815.
178. Ettinger AB. Structural causes of epilepsy. Tumors, cysts, stroke, and vascular malformations. Neurol Clin 1994;12:41–56.
179. Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, et al. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 1988;23:545–556.
180. Drake J, Hoffman HJ, Kobayashi J, et al. Surgical management of children with temporal lobe epilepsy and mass lesions. Neurosurgery 1987;21:792–797.
181. Duffner PK, Burger PC, Cohen ME, et al. Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery 1994;34:583–589.
182. Buetow PC, Smirniotopoulos JG, Done S. Congenital brain tumors: a review of 45 cases. Am J Neuroradiol 1990;11:793–799.
183. Zimmerman RA, Haselgrove JC, Bilaniuk LT, et al. Magnetization transfer suppression in gadolinium enhancement of the child’s brain. Proc XV Symposium Neuroradiologicum, 1994: 267–269.
184. Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–689.
185. Wang Z, Sutton LN, Cnaan A, et al. Proton MR spectroscopy of pediatric cerebellar tumors. Am J Neuroradiol 1995;16:1821–1833.
186. Sutton LN, Wang ZJ, Wehrli SL, et al. Proton spectroscopy of suprasellar tumors in pediatric patients. Neurosurgery 1997;41:388–394; discussion 394–395.
187. Girard N, Wang ZJ, Erbetta A, et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology 1998;40:121–125.
188. Lazareff JA, Gupta RK, Alger J. Variation of post-treatment H-MRSI choline intensity in pediatric gliomas. J Neurooncol 1999;41:291–298.
189. Rock JP, Hearshen D, Scarpace L, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51:912–919; discussion 919–920.
190. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–618.
191. Haacke M, Ogg R, Reichenbach J, et al. Susceptibility weighted imaging (SWI): a new means to enhance image contrast. In: Proceedings of the 10th Annual Meeting of ISMRM, Honolulu, HI, 2002;297.
192. Haacke M, Herigault G, Yu Y, et al. Observing tumor vascularity noninvasively using magnetic resonance imaging. Image Anal 2002;21:107–113.
193. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798.
194. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51.
195. Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711–716.
196. Huisman TA, Sorensen AG. Perfusion-weighted magnetic resonance imaging of the brain: techniques and application in children. Eur Radiol 2004;14:59–72.
197. Rollins NK, Lowry PA, Shapiro KN. Comparison of gadolinium-enhanced MR and thallium-201 single photon emission computed tomography in pediatric brain tumors. Pediatr Neurosurg 1995;22:8–14.
198. Maria BL, Drane WB, Quisling RJ, et al. Correlation between gadolinium-diethylenetriaminepentaacetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem glioma. J Child Neurol 1997;12:341–348.
199. Hustinx R, Alavi A. SPECT and PET imaging of brain tumors. Neuromaging Clin N Am. 1999;9:751–766.
200. Erdem E, Zimmerman RA, Haselgrove JC, et al. Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroimaging Clin North Am 2001;43:927–933.
201. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60.
202. Sutton LN, Lasner T, Hunter J, et al. Thirteen-year-old female with hemangioblastoma. Pediatr Neurosurg 1997;27:50–55.
203. Lesniak MS, Klem JM, Weingart J, et al. Surgical outcome following resection of contrast-enhanced pediatric brainstem gliomas. Pediatr Neurosurg 2003;39:314–322.
204. DiPaolo DP, Zimmerman RA, Rorke LB, et al. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995;195:721–724.
205. Hunter JV, Molloy PT, Needle MN. Neurofibromatosis type I and lesions of the corpus callosum in a pediatric population. 7th Annual European Neurofibromatosis Meeting, Paris, 1997. Abstract.
206. Gonen O, Wang ZJ, Viswanathan AK, et al. Three-dimensional multivoxel proton MR spectroscopy of the brain in children with neurofibromatosis type 1. Am J Neuroradiol 1999;20:1333–1341.
207. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41:143–149.
208. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol 1998;19:407–413.
209. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004;54:1111–1117; discussion 1117–1119.
210. Hurd RE, Freeman DM. Metabolite specific proton magnetic resonance imaging. Proc Natl Acad Sci 1989;86:4402–4406.
211. Ryner LN, Sorenson JA, Thomas MA. 3D localized 2D NMR spectroscopy on an MRI scanner. J Magn Reson B 1995;107:126–137.
212. Mayer D, Dreher W, Liebfritz D. Fast IH spectroscopic imaging combined with 2D correlation spectroscopy uncoupled in both frequency domains, Proc Intl Soc Mag Reson Med, 2000;8:370.
213. Skare S, Hedehus M, Moseley ME, et al. Condition number as a measure of noise performance of diffusion tensor data acquisition schemes with MRI. J Magn Reson 2000;147: 340–352.
214. Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 1999;30:115–124.
215. Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group. Neurosurgery 1993;33:1026–1029.
216. Lunsford LD. Diagnosis of mass lesions using the Leksell system. In: Lunsford LD, ed. Modern stereotactic surgery. Boston: Martinus Nijhoff, 1987:
217. Broggi G, Franzini A, Migliavacca F, et al. Stereotactic biopsy of deep brain tumors in infancy and childhood. Childs Brain 1983;10:92–98.
218. Jones RF, Stening WA, Brydon M. Endoscopic third ventriculostomy. Neurosurgery 1990;26:86–91.
219. Hopf NJ, Grunert P, Fries G, et al. Endoscopic third ventriculostomy: outcome analysis of 100 consecutive procedures. Neurosurgery 1999;44:795–804.
220. Dias MS, Albright AL. Management of hydrocephalus complicating childhood posterior fossa tumors. Pediatr Neurosci 1989;15:283–289.
221. Foy PM, Chadwick DW, Rajgopalan N, et al. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry 1992;55:753–757.
222. Nazar GB, Hoffman HJ, Becker LE, et al. Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 1990;72:408–417.
223. Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991;28:666–671.
224. Rousseau P, Habrand JL, Sarrazin D, et al. Treatment of intracranial ependymomas of children: review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994;28:381–386.
225. Sutton LN, Goldwein J, Perilongo G, et al. Prognostic factors in childhood ependymomas. Pediatr Neurosurg 1990;16:57–65.
226. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995;37:655–666.
227. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children’s Cancer Group. J Neurosurg 1998;88:695–703.
228. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999;21:203–211.
229. Wisoff JH, Boyett J, K. B, et al. Neurosurgical management and influence of extent of resection on survival in pediatric high-grade astrocytomas: a report on the CCG 934. J Neurosurg 1993;78:344 (abst).
230. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995;13:112–123.
231. Campbell JW, Pollack IF, Martinez AJ, et al. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996;38:258–264.
232. Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998;89:52–59.
233. Albright AL, Wisoff JH, Zeltzer P, et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children’s Cancer Group. Pediatr Neurosurg 1995;22:1–7.
234. Berry MP, Jenkin RD, Keen CW, et al. Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg 1981;55:43–51.
235. Bourne JP, Geyer R, Berger M, et al. The prognostic significance of postoperative residual contrast enhancement on CT scan in pediatric patients with medulloblastoma. J Neurooncol 1992;14:263–270.
236. Caputy AJ, McCullough DC, Manz HJ, et al. A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 1987;66: 80–87.
237. Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 1988;61:1992–1998.
238. Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464–469.
239. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-oncology 2003;5:153–160.
240. Packer RJ, Perilongo G, Johnson D, et al. Choroid plexus carcinoma of childhood. Cancer 1992;69:580–585.
241. Berger C, Thiesse P, Lellouch-Tubiana A, et al. Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery 1998;42:470–475.
242. Pencalet P, Sainte-Rose C, Lellouch-Tubiana A, et al. Papillomas and carcinomas of the choroid plexus in children. J Neurosurg 1998;88:521–528.
243. Cochrane DD, Gustavsson B, Poskitt KP, et al. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 1994;20:19–29.
244. Albright AL, Wisoff JH, Zeltzer PM, et al. Current neurosurgical treatment of medulloblastomas in children. A report from the Children’s Cancer Study Group. Pediatr Neurosci 1989;15:276–282.
245. Sanford RA. Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery 1994;21[Suppl 1]:39–43.
246. Albright AL, Sposto R, Holmes E, et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000;47:879–885.
247. Kelly PJ. Stereotactic craniotomy. Neurosurg Clin North Am 1990;1:781–799.
248. Barnett GH, Kormos DW, Steiner CP, et al. Use of a frameless, armless stereotactic wand for brain tumor localization with two-dimensional and three-dimensional neuroimaging. Neurosurgery 1993;33:674–678.
249. Martin AJ, Hall WA, Liu H, et al. Brain tumor resection: intraoperative monitoring with high-field-strength MR imaging-initial results. Radiology 2000;215:221–228.
250. Schneider W, Noll DC, Cohen JD. Functional topographic mapping of the cortical ribbon in human vision with conventional MRI scanners. Nature 1993;365:150–153.
251. Berger MS, Ojemann GA, Lettich E. Neurophysiological monitoring during astrocytoma surgery. Neurosurg Clin North Am 1990;1:65–80.
252. Schneider JH Jr, Raffel C, McComb JG. Benign cerebellar astrocytomas of childhood. Neurosurgery 1992;30:58–62.
253. Barrer SJ, Schut L, Sutton LN, et al. Re-operation for recurrent brain tumors in children. Childs Brain 1984;11:375–386.
254. Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 1999;31:131–136.
255. Pollack IF. Posterior fossa syndrome. Int Rev Neurobiol 1997;41:411–432.
256. Janssen G, Messing-Junger AM, Engelbrecht V, et al. Cerebellar mutism syndrome. Klin Padiatr 1998;210:243–247.
257. Turgut M. Transient “cerebellar” mutism. Childs Nerv Syst 1998;14:161–166.
258. Gajjar A, Sanford RA, Bhargava R, et al. Medulloblastoma with brain stem involvement: the impact of gross total resection on outcome. Pediatr Neurosurg 1996;25:182–187.
259. Pollack IF. Infratentorial primitive neuroectodermal tumors. New York: Thieme, 2001.
260. Steinbok P, Cochrane DD, Perrin R, et al. Mutism after posterior fossa tumour resection in children: incomplete recovery on long-term follow-up. Pediatr Neurosurg 2003;39:179–183.
261. Gelabert-Gonzalez M, Fernandez-Villa J. Mutism after posterior fossa surgery. Review of the literature. Clin Neurol Neurosurg 2001;103:111–114.
262. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853–863.
263. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464–476.
264. Thames HD Jr., Peters LJ, Withers HR, et al. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1983;9:127–138.
265. Taghian A, DuBois W, Budach W, et al. In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995;32:99–104.
266. Freeman CR. Hyperfractionated radiotherapy for diffuse intrinsic brain stem tumors in children. Pediatr Neurosurg 1996;24:103–110.
267. Halperin EC, Constine LS, Tarbell NJ, et al. Late effects of cancer treatment. In: Halperin EC, Constine LS, Tarbell NJ, et al., eds. Pediatric radiation oncology. New York: Raven Press, 1994:485–554.
268. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:959–964.
269. Fraass BA. The development of conformal radiation therapy. Med Phys 1995;22:1911–1921.
270. Thornton AF Jr, Hegarty TJ, Ten Haken RK, et al. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991;20:1309–1315.
271. Kirsch DG, Tarbell NJ. Conformal radiation therapy for childhood CNS tumors. Oncologist 2004;9:442–450.
272. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 1994;21:198–219.
273. Hadjipanayis CG, Kondziolka D, Gardner P, et al. Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg 2002;97:56–64.
274. Boethius J, Ulfarsson E, Rahn T, et al. Gamma knife radiosurgery for pilocytic astrocytomas. J Neurosurg 2002;97:677–680.
275. Chiou SM, Lunsford LD, Niranjan A, et al. Stereotactic radiosurgery of residual or recurrent craniopharyngioma, after surgery, with or without radiation therapy. Neuro-oncology 2001;3:159–166
276. Plowman PN, Wraith C, Royle N, et al. Stereotactic radiosurgery. IX. Craniopharyngioma: durable complete imaging responses and indications for treatment. Br J Neurosurg 1999; 13:352–358.
277. Miralbell R, Lomax A, Bortfeld T, et al. Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 1997;38:477–484.
278. Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol 2002;178:10–17.
279. Kortmann RD, Timmermann B, Taylor RE, et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol 2003;179:585–597.
280. Hasegawa T, Kondziolka D, Hadjipanayis CG, et al. Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery 2004;54:813–820; discussion 820–822.
281. Backlund EO, Axelsson B, Bergstrand CG, et al. Treatment of craniopharyngiomas—the stereotactic approach in a ten to twenty-three years’ perspective. I. Surgical, radiological and ophthalmological aspects. Acta Neurochir (Wien) 1989;99:11–19.
282. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Child 1973;48:757–767.
283. Mulhern RK, White HA, Glass JO, et al. Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 2004; 10:180–189.
284. Reddick WE, Glass JO, Langston JW, et al. Quantitative MRI assessment of leukoencephalopathy. Magn Reson Med 2002;47:912–920.
285. Schultheiss TE, Kun LE, Ang KK, et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995;31:1093–1112.
286. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a dynamic process. Radiat Res 2000;153:357–370.
287. Yuan H, Gaber MW, McColgan T, et al. Radiation-induced permeability and leukocyte adhesion in the rat blood-brain barrier: modulation with anti-ICAM-1 antibodies. Brain Res 2003;969:59–69.
288. Gaber MW, Yuan H, Killmar JT, et al. An intravital microscopy study of radiation-induced changes in permeability and leukocyte-endothelial cell interactions in the microvessels of the rat pia mater and cremaster muscle. Brain Res Brain Res Protoc 2004;13:1–10.
289. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399–408.
290. Mulhern RK, Palmer SL, Reddick WE, et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001;19: 472–479.
291. Packer RJ, Zimmerman RA, Kaplan A, et al. Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas. Data from the Childrens Cancer Group. Cancer 1993;71:2666–2674.
292. Fouladi M, Chintagumpala M, Laningham FH, et al. White matter lesions detected by magnetic resonance imaging following radiotherapy and high dose chemotherapy in children with medulloblastoma/PNET. J Clin Oncol 2005;22:4551–4560.
293. Helton K, Edwards M, Steen RG, et al. Late transient MRI findings associated with treatment in pediatric brain tumor patients. J Neurosurg 2004(in press).
294. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–122.
295. Leibel S, Sheline GE. Tolerance of the central and peripheral nervous system to therapeutic irradiation. Adv Radiat Biol 1987;12:257–288.
296. Ang KK, Stephens LC. Prevention and management of radiation myelopathy. Oncology (Huntingt) 1994;8:71–76.
297. Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother Oncol1994;30:17–25.
298. Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:755–763.
299. Merchant TE, Gould CJ, Xiong X, et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 2004;58:1194–207.
300. Grau C, Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 1996;36:515–517.
301. Miettinen S, Laurikainen E, Johansson EA. Radiotherapy enhances ototoxicity of cisplatin in children. Acta Otolaryngol Suppl 1997;529:90–94.
302. Wara WM, Irvine AR, Neger RE, et al. Radiation retinopathy. Int J Radiat Oncol Biol Phys 1979;5:81–83.
303. Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 1984;10:957–964.
304. Merchant TE, Goloubeva O, Pritchard DL, et al. Radiation dose-volume effects on growth hormone secretion. Int J Radiat Oncol Biol Phys 2002;52:1264–1270.
305. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328:87–94.
306. Bradbury M. The blood-brain barrier. Exp Physiol 1993;78:53–72.
307. de Boer A, Breimer D. The blood-brain barrier: clinical implications for drug delivery to the brain. J R Coll Phys London 1994;28:502–506.
308. Johansson B. The physiology of the blood-brain barrier. Adv Exp Med Biol 1990;27:25–39.
309. Bart J, Groen HJ, Hendrikse N, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000;26:449–462.
310. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999;96:3900–3905.
311. Schinkel A. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179–194.
312. Betz A. An overview of the multiple functions of the blood-brain barrier. NIDA Res Monogr 1992;120:5–72.
313. Angeletti RH, Novikoff PM, Juvvadi SR, et al. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci U S A 1997;94:283–286.
314. Pardridge W, Oldendorf W, Cancilla P, et al. Blood-brain barrier: interface between internal medicine and the brain. Ann Intern Med 1986;105:82–95.
315. Wijnholds J, deLange EC, Scheffer GL, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000;105:279–285.
316. Mellet L. Physiochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 1977;61:527–531.
317. Koch-Weser J, Sellers E. Binding of drugs to serum albumin. N Engl J Med 1976;294:311–316.
318. Poplack D, Bleyer W, Horowitz M. Pharmacology of antineoplastic agents in cerebrospinal fluid. New York: Plenum Press, 1980.
319. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783–789.
320. Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002;24:130–133.
321. Jarden JO, Dhawan V, Moeller JR, et al. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol 1989;25:239–245.
322. Nakagawa H, Groothuis DR, Owens ES, et al. Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 1987;7:687–701.
323. Groothuis DR, Wright DC, Ostertag CB. The effect of 125I interstitial radiotherapy on blood-brain barrier function in normal canine brain. J Neurosurg 1987;67:895–902.
324. Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 1984;15:362–366.
325. Emerich DF, Dean RL, Osborn C, et al. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001;40:105–123.
326. Papadakis V, Dunkel IJ, Cramer LD, et al. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 2000;26:153–160.
327. Finlay JL, Goldman S, Wong MC, et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children’s Cancer Group. J Clin Oncol 1996;14:2495–2503.
328. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998;16:2486–2493.
329. Abrey LE, Rosenblum MK, Papadopoulos E, et al. High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors. J Neurooncol 1999; 44:147–153.
330. Blaney S, Boyett J, Friedman H, et al. Phase 1 trial of intrathecal mafosfamide in infants with embryonal CNS tumors: a Pediatric Brain Tumor Consortium study. International Symposium on Pediatric Neuro-Oncology, London, England, 2002.
331. Shapiro W. Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol (Paris) 1992;148:428–434.
332. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008–1012.
333. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217–230.
334. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083–1099.
335. Neuwelt EA, Diehl JT, Vu LH, et al. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 1981;94:449–454.
336. Neuwelt EA, Balaban E, Diehl J, et al. Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery 1983;12:662–671.
337. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637–647.
338. Iwadate Y, Namba H, Saegusa T, et al. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neurooncol 1993;15:185–193.
339. Liu Y, Hashizume K, Chen Z, et al. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res 2001;23:379–387.
340. Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 1996;141:214–224.
341. Cloughesy TF, Black KL, Gobin YP, et al. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 1999;44:270–278; discussion 278–279.
342. Black KL, Chio CC. Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. Neurol Res 1992;14:402–404.
343. Gutman M, Laufer R, Eisenthal A, et al. Increased microvascular permeability induced by prolonged interleukin-2 administration is attenuated by the oxygen-free-radical scavenger dimethylthiourea. Cancer Immunol Immunother 1996;43:240–244.
344. de Vries H, Blom-Roosemalen M, van Osten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996;64:37–43.
345. Dean RL, Emerich DF, Hasler BP, et al. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro-oncology 1999;1:268–274.
346. Thomas J, Lind M, Ford J, et al. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumors. Cancer Chem Pharmacol 2000;45:284–290.
347. Hochberg FH, Parker LM, Takvorian T, et al. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 1981;54:455–460.
348. Bashir R, Hochberg FH, Linggood RM, et al. Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg 1988;68:917–919.
349. Kalifa C, Hartmann O, Demeocq F, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992;9:227–233.
350. Bergman I, Jakacki RI, Heller G, et al. Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. Med Pediatr Oncol 1997;29:563–567.
351. Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16: 210–221.
352. Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996;27:87–98.
353. Heideman RL, Douglass EC, Krance RA, et al. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. J Clin Oncol 1993;11:1458–1465.
354. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. J Clin Oncol 1998;16:222–228.
355. Mahoney DH Jr., Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996;14:382–388.
356. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001;19:2696–2704.
357. Finlay JL, August C, Packer R, et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol 1990;9:239–248.
358. Jakacki RI, Siffert J, Jamison C, et al. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J Neurooncol 1999;44:77–83.
359. Kedar A, Maria BL, Graham-Pole J, et al. High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med Pediatr Oncol 1994;23:428–436.
360. Poplack D, Riccardi R. Pharmacologic approaches to the treatment of central nervous system malignancy. Boston: Martinus Nijhoff, 1987.
361. Chabner B. The role of drugs in cancer treatment. Philadelphia: WB Saunders, 1982.
362. Collins J. Regional therapy: an overview. Boston: Martinus Nijhoff, 1987.
363. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195:73–83.
364. Blaney S, Poplack D, Godwin K, et al. The effect of body position on ventricular cerebrospinal fluid methotrexate concentration following intralumbar administration. J Clin Oncol 1995;13:177–179.
365. Blaney S, Berg S, Boddy A. CNS directed drug delivery. London: Arnold, 2004.
366. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79–88.
367. Giese A, Kucinski T, Knopp U, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004;66:351–360.
368. Rhines LD, Sampath P, Dolan ME, et al. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000;60:6307–6310.
369. Kaiser MG, Parsa AT, Fine RL, et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000;47:1391–1398; discussion 1398–1399.
370. Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000;46:683–691.
371. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93–103.
372. Kunwar S, Pai LH, Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 1993;79:569–576.
373. Laske DW, Ilercil O, Akbasak A, et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994;80:520–526.
374. Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157–2165.
375. Saris SC, Blasberg RG, Carson RE, et al. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 1991;74:763–772.
376. Mahaley MS Jr., Hipp SW, Dropcho EJ, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989;70:371–378.
377. Newton HB, Page MA, Junck L, et al. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989;7:39–45.
378. Kapp J, Vance R, Parker JL, et al. Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas. Neurosurgery 1982; 10:715–719.
379. Blacklock JB, Wright DC, Dedrick RL, et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg 1986;64:284–291.
380. Ross RL, Kapp JP, Hochberg F, et al. Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion. Neurosurgery 1983;12:512–514.
381. Li XN, Parikh S, Shu Q, et al. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 2004;10:1150–1159.
382. Mukherjee P, Das SK. Antiproliferative action of retinoic acid in cultured human brain tumour cells Gl-As-14(S). Cancer Lett 1990;52:83–89.
383. Agrawal A, Martell LA, Ross DA, et al. Retinoic acid modulation of proliferation and differentiation in brain tumors. Proc Am Assoc Cancer Res 1993;34:20.
384. Rodts GE Jr, Black KL. Trans retinoic acid inhibits in vivo tumour growth of C6 glioma in rats: effect negatively influenced by nerve growth factor. Neurol Res 1994;16:184–186.
385. Stockhammer G, Manley GT, Johnson R, et al. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 1995;83:672–681.
386. Samid D, Ram Z, Hudgins WR, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. 1994;54:891–895.
387. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288–2295.
388. Liu L, Shack S, Stetler-Stevenson WG, et al. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 1994;103:335–340.
389. Sidell N, Wada R, Han G, et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 1995;60:507–514.
390. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996;2:379–387.
391. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003;9:1033–1038.
392. Gumireddy K, Sutton LN, Phillips PC, et al. All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Clin Cancer Res 2003;9:4052–4059.
393. Hoi Sang U, Espiritu OD, Kelley PY, et al. The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 1995;82:841–846.
394. Atiba J, Jamil S, Meyskens FL. Transretinoic acid (tRA) in the treatment of malignant gliomas (MG): a phase II study. Proc Am Soc Clin Oncol 1994;13:178.
395. Phuphanich S, Scott C, Fischbach AJ, et al. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91–13) in patients with recurrent malignant astrocytoma. J Neurooncol 1997;34:193–200.
396. Hao Y, Creson T, Zhang L, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004;24:6590–6599.
397. Jansen MS, Nagel SC, Miranda PJ, et al. Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci U S A 2004;101:7199–7204.
398. Kieran M, Supko J, MacDonald T, et al. Phase I and pharmacokinetic study of intravenous SU5416 in pediatric central nervous system tumors. Proc Am Soc Clin Oncol 2003;22: 846(abst. 986).
399. Chintagumpala M, Bomgaars L, Aleksic A, et al. Phase I trial of carboplatin and thalidomide in children with refractory or recurrent solid tumors. J Clin Oncol 2004;22:4394–4400.
400. Purow B, Fine HA. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol Oncol Clin North Am 2004;8:1161–1181.
401. Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
402. Buchdunger E, Cioffi C, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–145.
403. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947–4952.
404. Heinrich M, Griffith D, Druker B, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–932.
405. Nistér M, Claesson-Welch L, Eriksson A, et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991;266: 16755–16763.
406. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–137.
407. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998;18:6090–7101.
408. Sartor CI, Zhou H, Kozlowska E, et al. 3rd Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;21:4265–4275.
409. Adam L, Vadlamudi R, Kondapaka SB, et al. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;23:28238–28246.
410. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027–8031.
411. Yang HY, Zhou BP, Hung MC, et al. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000;275:24735–24739.
412. Gilbertson R, Hill A, Hernan R, et al. ERBB1 is amplified and overexpressed in high grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003;9:3620–3624.
413. Gilbertson RJ, Jaros E, Perry RH, et al. Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur J Cancer 1997;33:609–615.
414. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705–712.
415. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998;58:3932–3941.
416. Yoffey JM, Courtice FC. Lymphatics, lymph and the lymphomyeloid complex. New York: Academic Press, 1970.
417. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984;38:293–298.
418. Pollack IF, Okada H, Chambers WH. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Pediatr Neurol 2000;7:131–143.
419. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1–54.
420. Medawar PB. Immunity to homologous grafted skin, III: the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58–69.
421. Fathallah-Shaykh H. New molecular strategies to cure brain tumors. Arch Neurol 1999; 56:449–453.
422. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209–2218.
423. Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89:42–51.
424. Yates AJ, Stephens RE, Elder PJ, et al. Effects of interferon and gangliosides on growth of cultured human glioma and fetal brain cells. Cancer Res 1985;45:1033–1039.
425. Yung WK, Steck PA, Kelleher PJ, et al. Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 1987;5:323–330.
426. Cook AW, Carter WA, Nidzgorski F, et al. Human brain tumor–derived cell lines: growth rate reduced by human fibroblast interferon. Science 1983;219:881–883.
427. Mahaley MS Jr., Dropcho EJ, Bertsch L, et al. Systemic beta-interferon therapy for recurrent gliomas: a brief report. J Neurosurg 1989;71:639–641.
428. Nagai M, Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 1984;7:55–64.
429. Olson JJ, James CD, Lawson D, et al. Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content. Int J Oncol 2004;25:419–427.
430. Mahaley MS Jr, Bertsch L, Cush S, et al. Systemic gamma-interferon therapy for recurrent gliomas. J Neurosurg 1988;69:826–829.
431. Farkkila M, Jaaskelainen J, Kallio M, et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994;70:138–141.
432. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175–182.
433. Yoshida S, Tanaka R, Takai N, et al. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988;48:5011–5016.
434. Saris SC, Spiess P, Lieberman DM, et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 1992;76:513–519.
435. Neuwelt EA, Specht HD, Barnett PA, et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 1987;20:885–895.
436. Colapinto EV, Zalutsky MR, Archer GE, et al. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab’)2 fragments of monoclonal antibody Mel-14. Cancer Res 1990;50:1822–1827.
437. Lashford LS, Davies AG, Richardson RB, et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988;61:857–868.
438. Johnson VG, Wrobel C, Wilson D, et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989;70:240–248.
439. Lowenstein PR, Cowen R, Thomas C, et al. The basic science of brain-tumour gene therapy. Biochem Soc Trans 1999;27:873–881.
440. Trojan J, Johnson TR, Rudin SD, et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993;259:94–97.
441. Yu JS, Wei MX, Chiocca EA, et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993;53:3125–3128.
442. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550–1552.
443. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354–1361.
444. Packer RJ, Raffel C, Villablanca JG, et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 2000;92:249–254.
445. Glick RP, Lichtor T, Mogharbel A, et al. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 1997;41:898–906.
446. Sampson JH, Ashley DM, Archer GE, et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 1997;41:1365–1372.
447. Benedetti S, Bruzzone MG, Pollo B, et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 1999;59:645–652.
448. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998;5:121–130.
449. Bozik M, Okada H, Pollack I. Mechanisms and relative potency of cytokine-modified brain tumor vaccines for eliciting CNS anti tumor immunoreactivity. Proc Soc Neurooncol 1997;2:12.
450. Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 2001;12:575–595.
451. Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 2003;64:13–20.
452. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177–1182.
453. Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998;78:196–201.
454. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725–1731.
455. Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neurooncology 1999;1:152–161.
456. Lashford LS, Campbell RH, Gattamaneni HR, et al. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 1996;74:219–223.
457. Marec-Berard P, Jouvet A, Thiesse P, et al. Supratentorial embryonal tumors in children under 5 years of age: an SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol 2002;38:83–90.
458. Duffner PK, Cohen ME, Myers MH, et al. Survival of children with brain tumors: SEER Program, 1973–1980. Neurology 1986;36:597–601.
459. Mason WP, Goldman S, Yates AJ, et al. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma—a report of the Children’s Cancer Group. J Neurooncol 1998;37:135–143.
460. White L, Kellie S, Gray E, et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG). J Pediatr Hematol Oncol 1998;20:125–130.
461. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 1998;22:1083–1092.
462. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004;22:2877–2884.
463. Cohen BH, Packer RJ, Siegel KR, et al. Brain tumors in children under 2 years: treatment, survival and long-term prognosis. Pediatr Neurosurg 1993;19:171–179.
464. Albright AL, Price RA, Guthkelch AN. Diencephalic gliomas of children. A clinicopathologic study. Contemp Neurosurg 1985;55:2789–2793.
465. Haddad SF, Menezes AH, Bell WE, et al. Brain tumors occurring before 1 year of age: a retrospective reviews of 22 cases in an 11-year period (1977–1987). Neurosurgery 1991;29: 8–13.
466. Reed UC, Rosemberg S, Gherpelli JL, et al. Brain tumors in the first two years of life: a review of forty cases. Pediatr Neurosurg 1993;19:180–185.
467. Tomita T, McLone DG. Brain tumors during the first twenty-four months of life. Neurosurgery 1985;17:913–919.
468. Deutsch M. Radiotherapy for primary brain tumors in very young children. Cancer 1982; 50:2785–2789.
469. Saran FH, Driever PH, Thilmann C, et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Int J Radiat Oncol Biol Phys 1998;42:959–967.
470. Bloom HJ, Glees J, Bell J, et al. The treatment and long-term prognosis of children with intracranial tumors: a study of 610 cases, 1950–1981. Int J Radiat Oncol Biol Phys 1990;18: 723–745.
471. Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol 1997;28:348–354.
472. Lannering B, Marky I, Nordborg C. Brain tumors in childhood and adolescence in west Sweden 1970–1984. Epidemiology and survival. Cancer 1990;66:604–609.
473. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998;16:1723–1728.
474. Mulhern RK, Hancock J, Fairclough D, et al. Neuropsychological status of children treated for brain tumors: a critical review and integrative analysis. Med Pediatr Oncol 1992;20: 181–191.
475. Clayton PE, Price DA, Shalet SM. Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 1987;62:222–226.
476. Shalet SM. Growth and hormonal status of children treated for brain tumours. Childs Brain 1982;9:284–293.
477. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 1994;12:1607–1615.
478. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children’s Research Hospital. J Clin Oncol 1999;17:3720–3728.
479. Goldwein JW, Radcliffe J, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899–904.
480. Xu W, Janss A, Packer RJ, et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neurooncology 2004;6:113–118.
481. Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998;28:215–222.
482. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004;22:3156–3162.
483. Ater JL, van Eys J, Woo SY, et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol 1997;32: 243–252.
484. Strother D, Kepner J, Aronin P, et al. Dose-intensive chemotherapy with ependymoma results of Pediatric Oncology Group study 9233. Proc Am Soc Clin Oncol 2000;19:585a.
485. Sanford RA, Horowitz ME, Kun LE, et al. Preoperative chemotherapy to facilitate the total resection of pediatric brain tumors. Concepts Pediatr Neurosurg 1989;9:139–152.
486. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461–3467.
487. McNeil DE, Cote TR, Clegg L, et al. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002;39:190–194.
488. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001;17:503–511.
489. Russell DS, Rubinstein LJ. Pathology of tumors of the nervous system, 5th ed. Baltimore: Williams & Wilkins, 1989.
490. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992;16:687–693.
491. Brown HG, Kepner JL, Perlman EJ, et al. “Large cell/anaplastic” medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857–865.
492. Eberhart C, Kratz J, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36–44.
493. Allen JC, Epstein F. Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients’ age and extent of disease on prognosis. J Neurosurg 1982;57:446–451.
494. Deutsch M, Reigel DH. The value of myelography in the management of childhood medulloblastoma. Cancer 1980;45:2194–2197.
495. Kleinman GM, Hochberg FH, Richardson EP Jr. Systemic metastases from medulloblastoma: report of two cases and review of the literature. Cancer 1981;48:2296–2309.
496. Campbell AN, Chan HS, Becker LE, et al. Extracranial metastases in childhood primary intracranial tumors. A report of 21 cases and review of the literature. Cancer 1984;53:974–981.
497. Tarbell NJ, Loeffler JS, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991;68:1600–1604.
498. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572–582.
499. Eberhart CG, Cohen KJ, Tihan T, et al. Medulloblastomas with systemic metastases: evaluation of tumor histopathology and clinical behavior in 23 patients. J Pediatr Hematol Oncol 2003;25:198–203.
500. Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994;91: 12867–12871.
501. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027–1035.
502. Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711–719.
503. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984–993.
504. Duffner PK, Kun LE, Burger PC, et al. Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. Pediatr Neurosurg 1995;22:189–196.
505. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys 2000;46:269–279.
506. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690–698.
507. Bouffet E, Gentet JC, Doz F, et al. Metastatic medulloblastoma: the experience of the French Cooperative M7 Group. Eur J Cancer 1994;30A:1478–1483.
508. Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 1996;38:265–271.
509. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 1999;17:2127–2136.
510. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832–845.
511. Gajjar A, Fouladi M, Walter AW, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999;17:1825–1828.
512. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166–178.
513. Jenkin D, Goddard K, Armstrong D, et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 1990;19:265–274.
514. Krischer JP, Ragab AH, Kun L, et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 1991;74:905–909.
515. McLaurin RL. Disadvantages of the preoperative shunt in posterior fossa tumors. Clin Neurosurg 1983;30:286–292.
516. Albright AL. The value of precraniotomy shunts in children with posterior fossa tumors. Clin Nuerosurg 1983;30:278–285.
517. Berger MS, Baumeister B, Geyer JR, et al. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 1991;74:872–877.
518. Tomita T, Yasue M, Engelhard HH, et al. Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 1988;61:744–749.
519. Jung HL, Wang KC, Kim SK, et al. Loss of heterozygosity analysis of chromosome 17p13.1–13.3 and its correlation with clinical outcome in medulloblastomas. J Neurooncol 2004;67:41–46.
520. Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478–2485.
521. Pingoud-Meier C, Lang D, Janss AJ, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 2003;9:6401–6409.
522. Fernandez-Teijeiro A, Betensky RA, Sturla LM, et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22: 994–998.
523. Ellison DW, Clifford SC, Gajjar A, et al. What’s new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003;7:53–66.
524. Wisoff JH, Epstein FJ. Pseudobulbar palsy after posterior fossa operation in children. Neurosurgery 1984;15:707–709.
525. Pollack IF, Lunsford LD, Slamovits TL, et al. Stereotaxic intracavitary irradiation for cystic craniopharyngiomas. J Neurosurg 1988;68:227–233.
526. Bouffet E, Bernard JL, Frappaz D, et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992;24:79–85.
527. Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004–3011.
528. Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 2003;21:3079–3083.
529. Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Proceedings of the 45th Annual ASTRO Meeting 2003;57:S194–S195.
530. Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 2004;58:1161–1164.
531. Miralbell R, Bleher A, Huguenin P, et al. Pediatric medulloblastoma: radiation treatment technique and patterns of failure. Int J Radiat Oncol Biol Phys 1997;37:523–529.
532. Allen JC, Helson L, Jereb B. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial. Cancer 1983;52:2001–2006.
533. Loeffler JS, Kretschmar CS, Sallan SE, et al. Pre-radiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int J Radiat Oncol Biol Phys 1988;15:177–181.
534. Pendergrass TW, Milstein JM, Geyer JR, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 1987;5:1221–1231.
535. Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990;8:330–336.
536. Mosijczuk AD, Nigro MA, Thomas PR, et al. Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. Cancer 1993;72:2755–2762.
537. Heideman RL, Kovnar EH, Kellie SJ, et al. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 1995;13:2247–2254.
538. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003;21:1581–1591.
539. Hartsell WF, Gajjar A, Heideman RL, et al. Patterns of failure in children with medulloblastoma: effects of preirradiation chemotherapy. Int J Radiat Oncol Biol Phys 1997;39: 15–24.
540. Kun LE. Medulloblastoma—challenges in radiation therapy and the addition of chemotherapy. Int J Radiat oncol Biol Phys 2000;46:261–263.
541. Packer RJ, Sutton LN, Goldwein JW, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:433–440.
542. Prados MD, Wara W, Edwards MS, et al. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy. Pediatr Neurosurg 1996;25:174–181.
543. Gaffney CC, Sloane JP, Bradley NJ, et al. Primitive neuroectodermal tumours of the cerebrum. Pathology and treatment. J Neurooncol 1985;3:23–33.
544. Yang HJ, Nam DH, Wang KC, et al. Supratentorial primitive neuroectodermal tumor in children: clinical features, treatment outcome and prognostic factors. Childs Nerv Syst 1999;15:377–383.
545. Pollack IF. Brain tumors in children. N Engl J Med 1994;331:1500–1507.
546. Bruno LA, Rorke LB, Norris DG. Primitive neuroectodermal tumors of infancy and childhood. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. Boston: Nijhoff, 1981:265–267.
547. Duffner PK, Cohen ME, Heffner RR, et al. Primitive neuroectodermal tumors of childhood. An approach to therapy. J Neurosurg 1981;55:376–381.
548. Dirks PB, Harris L, Hoffman HJ, et al. Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 1996;29:75–84.
549. Paulino AC, Melian E. Medulloblastoma and supratentorial primitive neuroectodermal tumors: an institutional experience. Cancer 1999;86:142–148.
550. Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Children’s Cancer Group randomized trial. J Clin Oncol 1995;13:1687–1696.
551. Tomita T, McLone DG, Yasue M. Cerebral primitive neuroectodermal tumors in childhood. J Neurooncol 1988;6:233–243.
552. Knapp J, Daisy F, van Eys J. Primitive neuroectodermal tumors of brain in childhood: literature review and the MD Anderson experience. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:215.
553. Parker JC Jr, Mortara RH, McCloskey JJ. Biological behavior of the primitive neuroectodermal tumors: significant supratentorial childhood gliomas. Surg Neurol 1975;4:383–388.
554. Humphrey GB, Dehner LP, Kaplan RJ. Overview on the management of primitive neuroectodermal tumors. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:289.
555. Wald B, Siegle SE, Isaacs H. Cerebral primitive neuroectodermal tumor (primary cerebral neuroblastoma). In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:229.
556. Wara WM, Edwards MS, Surti NR. Primary cerebral neuroblastoma. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981: 225.
557. Baum ES, Morgan ER, DalCanto MC. Review and experience with primitive neuroectodermal tumors of childhood. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:238.
558. Priest J, Dehner LP, Sung JH. Primitive neuroectodermal tumors (embryonal gliomas) of childhood: a clinicopathologic study of 12 cases. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:247–264.
559. Ganti SR, Silver AJ, Diefenbach P, et al. Computed tomography of primitive neuroectodermal tumors. Am J Neuroradiol 1983;4:819–821.
560. Jenkin D. Primitive neuroectodermal tumors of childhood. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:243.
561. Jakacki RI. Pineal and nonpineal supratentorial primitive neuroectodermal tumors. Childs Nerv Syst 1999;15:586–591.
562. Reddy AT, Janss AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000;88:2189–2193.
563. Kosnik EJ, Boesel CP, Bay J, et al. Primitive neuroectodermal tumors of the central nervous system in children. J Neurosurg 1978;48:741–746.
564. Berger MS, Edwards MS, Wara WM, et al. Primary cerebral neuroblastoma. Long-term follow-up review and therapeutic guidelines. J Neurosurg 1983;59:418–423.
565. Sexauer CP, Drous HF, Kaplan RJ. Supratentorial primitive neuroectodermal tumor: clinical response to vincristine, cyclophosphamide, and BCNU. In: Humphrey GB, Dehner LP, Grindey GB, eds. Pediatric oncology. The Hague: Martinus Nijhoff, 1981:235.
566. Ashley DM, Longee D, Tien R, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Med Pediatr Oncol 1996;26:387–392.
567. Judkins AR, Mauger J, Ht A, et al. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004;28:644–650.
568. Tekautz T, Fuller C, Fouladi M, et al. Atypical teratoid/rhabdoid tumors (AT/RT): improved survival in children .3 years old with radiation therapy and high dose alkylator based chemotherapy. J Clin Oncol 2005;23:1491–1499.
569. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002;24:337–342.
570. Perilongo G, Massimino M, Sotti G, et al. Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol 1997;29:79–85.
571. Sala F, Talacchi A, Mazza C, et al. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neurosurg 1998;28:135–142.
572. Kun LE, Kovnar EH, Sanford RA. Ependymomas in children. Pediatr Neurosci 1988;14: 57–63.
573. Bouffet E, Perilongo G, Canete A, et al. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319–329.
574. Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990;19:1497–1502.
575. Bergsagel DJ, Finegold MJ, Butel JS, et al. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 1992;326: 988–993.
576. Merchant TE, Jenkins JJ, Burger PC, et al. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 2002;53:52–57.
577. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989;70:31–36.
578. Rawlings CE III, Giangaspero F, Burger PC, et al. Ependymomas: a clinicopathologic study. Surg Neurol 1988;29:271–281.
579. Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991;21:825–830.
580. Merchant TE, Haida T, Wang MH, et al. Anaplastic ependymoma: treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg 1997;86:943–949.
581. Hukin J, Epstein F, Lefton D, et al. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998;29:40–45.
582. Korshunov A, Golanov A, Sycheva R, et al. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004;100:1230–1237.
583. McLaughlin MP, Buatti JM, Marcus RB Jr, et al. Outcome after radiotherapy of primary spinal cord glial tumors. Radiat Oncol Investig 1998;6:276–280.
584. Needle MN, Goldwein JW, Grass J, et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 1997;80:341–347.
585. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001;158:1137–1143.
586. Nagib MG, O’Fallon MT. Posterior fossa lateral ependymoma in childhood. Pediatr Neurosurg 1996;24:299–305.
587. Sanford RA, Kun LE, Heideman RL, et al. Cerebellar pontine angle ependymoma in infants. Pediatr Neurosurg Pediatr Neurosurg 1997;27:84–91.
588. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg 2000;93:605–613.
589. Tomita T, McLone DG, Das L, et al. Benign ependymomas of the posterior fossa in childhood. Pediatr Neurosci 1988;14:277–285.
590. Pollack IF, Claassen D, al Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 1995;82:536–547.
591. Wallner KE, Wara WM, Sheline GE, et al. Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. Int J Radiat Oncol Biol Phys 1986;12:1937–1941.
592. Merchant TE, Kiehna EN, Thompson SJ, et al. Pediatric low-grade and ependymal spinal cord tumors. Pediatr Neurosurg 2000;32:30–36.
593. Nadkarni TD, Rekate HL. Pediatric intramedullary spinal cord tumors. Critical review of the literature. Childs Nerv Syst 1999;15:17–28.
594. Sexauer CL, Khan A, Burger PC, et al. Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer 1985;56:1497–1501.
595. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep 1987;71:1039–1042.
596. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999;15:563–570.
597. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, et al. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 1996;27:8–14.
598. Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003;98:1170–1174.
599. Freeman CR, Farmer JP, Montes J. Low-grade astrocytomas in children: evolving management strategies. Int J Radiat Oncol Biol Phys 1998;41:979–987.
600. Campbell JW, Pollack IF. Cerebellar astrocytomas in children. J Neurooncol 1996;28:223–231.
601. Wallner KE, Gonzales MF, Edwards MS, et al. Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988;69:171–176.
602. Farwell JR, Dohrmann GJ, Flannery JT. Central nervous system tumors in children. Cancer 1977;40:3123–3132.
603. Griffin TW, Beaufait D, Blasko JC. Cystic cerebellar astrocytomas in childhood. Cancer 1979;44:276–280.
604. Smoots DW, Geyer JR, Lieberman DM, et al. Predicting disease progression in childhood cerebellar astrocytoma. Childs Nerv Syst 1998;14:636–648.
605. Dohrmann GJ, Farwell JR, Flannery JT. Astrocytomas in childhood: a population-based study. Surg Neurol 1985;23:64–68.
606. Gajjar A, Sanford RA, Heideman R, et al. Low-grade astrocytoma: a decade of experience at St. Jude Children’s Research Hospital. J Cliin Oncol 1997;15:2792–2799.
607. Gajjar A, Bhargava R, Jenkins JJ, et al. Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 1995;83:67–71.
608. Civitello LA, Packer RJ, Rorke LB, et al. Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988;38:562–566.
609. Pollack IF, Hurtt M, Pang D, et al. Dissemination of low grade intracranial astrocytomas in children. Cancer 1994;73:2869–2878.
610. Rutka JT, George RE, Davidson G, et al. Low-grade astrocytoma of the tectal region as an unusual cause of knee pain: case report. Neurosurgery 1991;29:608–612.
611. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 1979;44:1839–1852.
612. Komotar RJ, Burger PC, Carson BS, et al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 2004;54:72–79; discussion 79–80.
613. Tihan T, Fisher PG, Kepner JL, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 1999;58:1061–1068.
614. Becker LE, Yates AJ. Astrocytic tumors in children. In: Finegold M, ed. Pathology of neoplasia in children and adolescents. Philadelphia: WB Saunders, 1986:373.
615. Bernell WR, Kepes JJ, Seitz EP. Late malignant recurrence of childhood cerebellar astrocytoma. Report of two cases. J Neurosurg 1972;37:470–474.
616. Scott RM, Ballantine HT Jr. Cerebellar astrocytoma: malignant recurrence after prolonged postoperative survival. Case report. J Neurosurg 1973;39:777–779.
617. Burger P. Atlas of tumor pathology: tumors of the central nervous system. Washington, DC: Armed Forces Institute of Pathology, 1993.
618. Tice H, Barnes PD, Goumnerova L, et al. Pediatric and adolescent oligodendrogliomas. AJNR Am J Neuroradiol 1993;14:1293–1300.
619. Jay V, Squire J, Becker LE, et al. Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Report of a case with flow cytometric and cytogenetic analysis. Cancer 1994;73:2862–2868.
620. Schwartz AM, Ghatak NR. Malignant transformation of benign cerebellar astrocytoma. Cancer 1990;65:333–336.
621. Hirsch JF, Sainte RC, Pierre-Kahn A, et al. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989;70:568–572.
622. Sgouros S, Fineron PW, Hockley AD. Cerebellar astrocytoma of childhood: long-term follow-up. Childs Nerv Syst 1995;11:89–96.
623. Laws ER Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984;61:665–673.
624. Winston K, Gilles FH, Leviton A, et al. Cerebellar gliomas in children. J Natl Cancer Inst 1977;58:833–838.
625. Conway PD, Oechler HW, Kun LE, et al. Importance of histologic condition and treatment of pediatric cerebellar astrocytoma. Cancer 1991;67:2772–2775.
626. Gjerris F, Klinken L. Long-term prognosis in children with benign cerebellar astrocytoma. J Neurosurg 1978;49:179–184.
627. Hayostek CJ, Shaw EG, Scheithauer B, et al. Astrocytomas of the cerebellum. A comparative clinicopathologic study of pilocytic and diffuse astrocytomas. Cancer 1993;72:856–869.
628. Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853–861.
629. Bowers DC, Gargan L, Kapur P, et al. Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol 2003;21:2968–2973.
630. Prados MD, Krouwer HG, Edwards MS, et al. Proliferative potential and outcome in pediatric astrocytic tumors. J Neurooncol 1992;13:277–282.
631. Pencalet P, Maixner W, Sainte-Rose C, et al. Benign cerebellar astrocytomas in children. J Neurosurg 1999;90:265–273.
632. Garcia DM, Latifi HR, Simpson JR, et al. Astrocytomas of the cerebellum in children. J Neurosurg 1989;71:661–664.
633. Gjerris F. Clinical aspects and long-term prognosis in supratentorial tumors of infancy and childhood. Acta Neurol Scand 1978;57:445–470.
634. Fazekas JT. Treatment of grades I and II brain astrocytomas. The role of radiotherapy. Int J Radiat Oncol Biol Phys 1977;2:661–666.
635. Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 1991;28:496–501.
636. Packer RJ, Sutton LN, Patel KM, et al. Seizure control following tumor surgery for childhood cortical low-grade gliomas. J Neurosurg 1994;80:998–1003.
637. Berger MS, Ghatan S, Haglund MM, et al. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993;79:62–69.
638. Leibel SA, Sheline GE, Wara WM, et al. The role of radiation therapy in the treatment of astrocytomas. Cancer 1975;35:1551–1557.
639. Garcia DM, Marks JE, Latifi HR, et al. Childhood cerebellar astrocytomas: is there a role for postoperative irradiation? Int J Radiat Oncol Biol Phys 1990;18:815–818.
640. Geissinger JD. Astrocytomas of the cerebellum in children. Long-term study. Arch Neurol 1971;24:125–135.
641. Sutton LN, Schut L. Cerebellar astrocytomas. In: McLaurin RL, Vennes JL, Schut L, eds. Pediatric neurosurgery: surgery of the developing nervous system. 2nd ed. Philadelphia: WB Saunders, 1989:338.
642. Sutton LN, Packer RJ, Rorke LB, et al. Cerebral gangliogliomas during childhood. Neurosurgery 1983;13:124–128.
643. VandenBerg SR. Desmoplastic infantile ganglioglioma and desmoplastic cerebral astrocytoma of infancy. Brain Pathol 1993;3:275–281.
644. Haddad SF, Moore SA, Menezes AH, et al. Ganglioglioma: 13 years of experience. Neurosurgery 1992;31:171–178.
645. Kalyan-Raman UP, Olivero WC. Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up. Neurosurgery 1987;20: 428–433.
646. Chintagumpala MM, Armstrong D, Miki S, et al. Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg 1996;24:306–313.
647. Cappelli C, Grill J, Raquin M, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child 1998;79:334–338.
648. Merchant TE, Zhu Y, Thompson SJ, et al. Preliminary results from a Phase II trail of conformal radiation therapy for pediatric patients with localised low-grade astrocytoma and ependymoma. Int J Radiat Oncol Biol Phys 2002;52:325–332.
649. Fouladi M, Wallace D, Langston JW, et al. Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 2003;15:1084–1092.
650. Tao ML, Barnes PD, Billett AL, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys 1997;39:579–587.
651. Hoffman HJ, Humphreys RP, Drake JM, et al. Optic pathway/hypothalamic gliomas: a dilemma in management. Pediatr Neurosurg 1993;19:186–195.
652. Pollack IF, Hoffman HJ, Humphreys RP, et al. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg 1993;78:859–863.
653. Dunbar SF, Tarbell NJ, Kooy HM, et al. Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys 1994;30:531–539.
654. Grabb PA, Lunsford LD, Albright AL, et al. Stereotactic radiosurgery for glial neoplasms of childhood. Neurosurgery 1996;38:696–701; discussion 701–702.
655. Kirsch DG, Tarbell NJ. New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy. Pediatr Blood Cancer 2004;42:461–464.
656. Dirks PB, Jay V, Becker LE, et al. Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 1994;34:68–78.
657. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992;10:249–256.
658. Castello MA, Schiavetti A, Varrasso G, et al. Chemotherapy in low-grade astrocytoma management. Childs Nerv Syst 1998;14:6–9.
659. McCowage G, Tien R, McLendon R, et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Med Pediatr Oncol 1996;27:32–39.
660. Gajjar A, Heideman RL, Kovnar EH, et al. Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg 1993;19:113–118.
661. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747–754.
662. Pons MA, Finlay JL, Walker RW, et al. Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. J Neurooncol 1992;14:151–158.
663. Longee DC, Friedman HS, Albright RE Jr, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990;72:583–588.
664. Brown MT, Friedman HS, Oakes WJ, et al. Chemotherapy for pilocytic astrocytomas. Cancer 1993;71:3165–3172.
665. Chamberlain MC. Recurrent cerebellar gliomas: salvage therapy with oral etoposide. J Child Neurol 1997;12:200–204.
666. Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997;32:235–241.
667. Kuo DJ, Weiner HL, Wisoff J, et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 2003;25:372–378.
668. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646–651.
669. Weiss L, Sagerman RH, King GA, et al. Controversy in the management of optic nerve glioma. Cancer 1987;59:1000–1004.
670. Alshail E, Rutka JT, Becker LE, et al. Optic chiasmatic-hypothalamic glioma. Brain Pathol 1997;7:799–806.
671. Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984;91:929–935.
672. Housepian EM, Chi TL. Neurofibromatosis and optic pathways gliomas. J Neurooncol 1993;15:51–55.
673. Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995;127:718–722.
674. Rush JA, Younge BR, Campbell RJ, et al. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982;89:1213–1219.
675. Danoff BF, Kramer S, Thompson N. The radiotherapeutic management of optic nerve gliomas in children. Int J Radiat Oncol Biol Phys 1980;6:45–50.
676. Oxenhandler DC, Sayers MP. The dilemma of childhood optic gliomas. J Neurosurg 1978;48:34–41.
677. Tenny RT, Laws ER Jr, Younge BR, et al. The neurosurgical management of optic glioma. Results in 104 patients. J Neurosurg 1982;57:452–458.
678. Packer RJ, Savino PJ, Bilaniuk LT, et al. Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain 1983;10:393–403.
679. Fletcher WA, Imes RK, Hoyt WF. Chiasmal gliomas: appearance and long-term changes demonstrated by computerized tomography. J Neurosurg 1986;65:154–159.
680. Chan MY, Foong AP, Heisey DM, et al. Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis. Pediatr Neurosurg 1998;29:23–28.
681. Alvord EC Jr, Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients’ age, tumor site, and treatment. J Neurosurg 1988;68:85–98.
682. Berger MS, Deliganis AV, Dobbins J, et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784–1791.
683. Imes RK, Hoyt WF. Childhood chiasmal gliomas: update on the fate of patients in the 1969 San Francisco Study. Br J Ophthalmol 1986;70:179–182.
684. Jenkin D, Angyalfi S, Becker L, et al. Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 1993;25:215–225.
685. Janss AJ, Grundy R, Cnaan A, et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995;75:1051–1059.
686. Guillamo JS, Creange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003;126:152–160.
687. Medlock MD, Madsen JR, Barnes PD, et al. Optic chiasm astrocytomas of childhood. 1. Long-term follow-up. Pediatr Neurosurg 1997;27:121–128.
688. Thiagalingam S, Flaherty M, Billson F, et al. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004;111:568–577.
689. Wong JY, Uhl V, Wara WM, et al. Optic gliomas. A reanalysis of the University of California, San Francisco experience. Cancer 1987;60:1847–1855.
690. Allen JC. Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg 2000;32:154–162.
691. Wisoff JH, Abbott R, Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 1990;73:661–667.
692. Khafaga Y, Hassounah M, Kandil A, et al. Optic gliomas: a retrospective analysis of 50 cases. Int J Radiat Oncol Biol Phys 2003;56:807–812.
693. Packer RJ, Bilaniuk LT, Cohen BH, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis 1988;1:212–222.
694. Dosoretz DE, Blitzer PH, Wang CC, et al. Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases. Cancer 1980;45:1467–1471.
695. Sutton LN, Molloy PT, Sernyak H, et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg 1995;83:583–589.
696. Bataini JP, Delanian S, Ponvert D. Chiasmal gliomas: results of irradiation management in 57 patients and review of literature. Int J Radiat Oncol Biol Phys 1991;21:615–623.
697. Packer RJ. Chemotherapy: low-grade gliomas of the hypothalamus and thalamus. Pediatr Neurosurg 2000;32:259–263.
698. Grill J, Laithier V, Rodriguez D, et al. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 2000;159:692–696.
699. Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 1993;79:32–35.
700. Loeffler JS, Smith AR, Suit HD. The potential role of proton beams in radiation oncology. Semin Oncol 1997;24:686–695.
701. Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988;23:79–85.
702. Mahoney DH Jr., Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neurooncology 2000;2:213–220.
703. Petronio J, Edwards MS, Prados M, et al. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 1991;74:701–708.
704. Kato T, Sawamura Y, Tada M, et al. Cisplatin/vincristine chemotherapy for hypothalamic/visual pathway astrocytomas in young children. J Neurooncol 1998;37:263–270.
705. Walter AW, Gajjar A, Reardon DA, et al. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children’s Research Hospital. J Pediatr Hematol Oncol 2000;22:247–251.
706. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995;13:2072–2076.
707. Heideman RL, Kuttesch J Jr, Gajjar AJ, et al. Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 1997;80:497–504.
708. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989;7:165–177.
709. Dropcho EJ, Wisoff JH, Walker RW, et al. Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann Neurol 1987;22:355–364.
710. Marchese MJ, Chang CH. Malignant astrocytic gliomas in children. Cancer 1990;65:2771–2778.
711. Kandt RS, Shinnar S, D’Souza BJ, et al. Cerebrospinal metastases in malignant childhood astrocytomas. J Neurooncol 1984;2:123–128.
712. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487–493.
713. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338–343.
714. Burger PC, Heinz ER, Shibata T, et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988;68:698–704.
715. Burger PC, Dubois PJ, Schold SC Jr., et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983;58:159–169.
716. Halperin EC, Bentel G, Heinz ER, et al. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989;17:1347–1350.
717. Curran WJ Jr., Scott CB, Horton J, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 1992;12:219–227.
718. Phuphanich S, Edwards MS, Levin VA, et al. Supratentorial malignant gliomas of childhood. Results of treatment with radiation therapy and chemotherapy. J Neurosurg 1984; 60:495–499.
719. Pollack IF, Boyett JM, Yates AJ, et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro-oncology 2003;5:197–207.
720. Pollack IF, Hamilton RL, Burnham J, et al. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 2002; 50:1238–1244; discussion 1244–1245.
721. Raffel C, Frederick L, O’Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5:4085–4090.
722. Bredel M, Pollack IF, Campbell JW, et al. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res 1997;3:2157–2164.
723. Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004;59:126–137.
724. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667–1673.
725. Florell RC, Macdonald DR, Irish WD, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992;76:179–183.
726. Fontanesi J, Heideman RL, Muhlbauer M, et al. High-activity 125I interstitial irradiation in the treatment of pediatric central nervous system tumors: a pilot study. Pediatr Neurosurg 1995;22:289–297; discussion 98.
727. Loeffler JS, Alexander E 3rd, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379–1385.
728. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992;31:78–82.
729. Kyritsis AP, Yung WK, Bruner J, et al. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993;32:365–370.
730. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839–845.
731. Pollack IF, Finkelstein SD, Burnham J, et al. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort. Pediatr Neurosurg 2003;39:114–121.
732. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996;78:527–531.
733. Prados MD, Warnick RE, Mack EE, et al. Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial. Am J Clin Oncol 1996;19:609–612.
734. Heideman RL, Douglass EC, Langston JA, et al. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. J Neurooncol 1995;25:77–84.
735. Chastagner P, Sommelet-Olive D, Kalifa C, et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 1993;21:49–53.
736. Walker MD, Alexander E Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333–343.
737. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684–4691.
738. Wagner S, Erdlenbruch B, Langler A, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer 2004;100:1750–1757.
739. Gajjar A, Chintagumpala MM, Bowers DC, et al. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 2003;97:2374–2380.
740. Pollack IF, Boyett JM, Finlay JL. Chemotherapy for high-grade gliomas of childhood. Childs Nerv Syst 1999;15:529–544.
741. Grovas AC, Boyett JM, Lindsley K, et al. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children’s Cancer Group. Med Pediatr Oncol 1999;33:83–87.
742. Bouffet E, Mottolese C, Jouvet A, et al. Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 1997;33:91–95.
743. Chintagumpala M. Responses to procarbazine in newly-diagnosed patients with high-grade gliomas: a Pediatric Oncology Group Study. Proc Am Soc Clin Oncol, 2000;18: 558a.
744. Chintagumpala M, Stewart C, Burger P, et al. Responses to topotecan in newly-diagnosed patients with high-grade gliomas—a Pediatric Oncology Group (POG) study. The 9th International Symposium on Pediatric Neuro-Oncology. June 11–14, 2000; San Francisco, CA. Abstract.
745. Pollack IF, Shultz B, Mulvihill JJ. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 1996;46:1652–1660.
746. Molloy PT, Bilaniuk LT, Vaughan SN, et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995;45:1897–1902.
747. Robertson PL, Muraszko KM, Brunberg JA, et al. Pediatric midbrain tumors: a benign subgroup of brainstem gliomas. Pediatr Neurosurg 1995;22:65–73.
748. Vandertop WP, Hoffman HJ, Drake JM, et al. Focal midbrain tumors in children. Neurosurgery 1992;31:186–194.
749. Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg 1990;16:73–83.
750. May PL, Blaser SI, Hoffman HJ, et al. Benign intrinsic tectal “tumors” in children. J Neurosurg 1991;74:867–871.
751. Fischbein NJ, Prados MD, Wara W, et al. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg 1996;24:9–23.
752. Boydston WR, Sanford RA, Muhlbauer MS, et al. Gliomas of the tectum and periaqueductal region of the mesencephalon. Pediatr Neurosurg 1991;17:234–238.
753. Lassman LP, Arjona VE. Pontine gliomas of childhood. Lancet 1967;1:913–915.
754. Epstein FJ, Farmer JP. Brain-stem glioma growth patterns. J Neurosurg 1993;78:408–412.
755. Abbott R, Shiminski-Maher T, Wisoff JH, et al. Intrinsic tumors of the medulla: surgical complications. Pediatr Neurosurg 1991;17:239–244.
756. Epstein F, McCleary EL. Intrinsic brain-stem tumors of childhood: surgical indications. J Neurosurg 1986;64:11–15.
757. Packer RJ, Nicholson HS, Johnson DL, et al. Dilemmas in the management of childhood brain tumors: brainstem gliomas. Pediatr Neurosurg 1991;17:37–43.
758. Robertson PL, Allen JC, Abbott IR, et al. Cervicomedullary tumors in children: a distinct subset of brainstem gliomas. Neurology 1994;44:1798–1803.
759. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat oncol Biol Phys 1998;40:265–271.
760. Sanford RA, Bebin J, Smith RW. Pencil gliomas of the aqueduct of Sylvius. Report of two cases. J Neurosurg 1982;57:690–696.
761. Hoffman HJ, Becker L, Craven MA. A clinically and pathologically distinct group of benign brain stem gliomas. Neurosurgery 1980;7:243–248.
762. Khatib ZA, Heideman RL, Kovnar EH, et al. Predominance of pilocytic histology in dorsally exophytic brain stem tumors. Pediatr Neurosurg 1994;20:2–10.
763. Stroink AR, Hoffman HJ, Hendrick EB, et al. Diagnosis and management of pediatric brain-stem gliomas. J Neurosurg 1986;65:745–750.
764. Soffer D, Sahar A. Cystic glioma of the brain stem with prolonged survival. Neurosurgery 1982;10:499–502.
765. Edwards MS, Wara WM, Ciricillo SF, et al. Focal brain-stem astrocytomas causing symptoms of involvement of the facial nerve nucleus: long-term survival in six pediatric cases. J Neurosurg 1994;80:20–25.
766. Albright AL, Price RA, Guthkelch AN. Brain stem gliomas of children. A clinicopathological study. Cancer 1983;52:2313–2319.
767. Littman P, Jarrett P, Bilaniuk LT, et al. Pediatric brain stem gliomas. Cancer 1980;45:2787–2792.
768. Pierre-Kahn A, Hirsch JF, Vinchon M, et al. Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg 1993;79:845–852.
769. Silbergeld D, Berger M, Griffin B, et al. Brainstem glioma with multiple intraspinal metastases during life: case report and review of the literature. Pediatr Neurosci 1988;14:103–107.
770. Packer RJ, Allen J, Nielsen S, et al. Brainstem glioma: clinical manifestations of meningeal gliomatosis. Ann Neurol 1983;14:177–182.
771. Zagzag D, Miller DC, Knopp E, et al. Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics 2000;106:1045–1053.
772. Freeman CR, Kepner J, Kun LE, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 2000;47:561–564.
773. Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a Childrens Cancer Group phase I/II study. Cancer 1996;77:2150–2156.
774. Pollack IF, Pang D, Albright AL. The long-term outcome in children with late-onset aqueductal stenosis resulting from benign intrinsic tectal tumors. J Neurosurg 1994;80:681–688.
775. Squires LA, Allen JC, Abbott R, et al. Focal tectal tumors: management and prognosis. Neurology 1994;44:953–956.
776. Epstein F, Wisoff J. Intra-axial tumors of the cervicomedullary junction. J Neurosurg 1987;67:483–487.
777. Epstein F, Wisoff JH. Intrinsic brainstem tumors in childhood: surgical indications. J Neurooncol 1988;6:309–317.
778. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1993;27:197–206.
779. Packer RJ, Boyett JM, Zimmerman RA, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 1993;72:1414–1421.
780. Shrieve DC, Wara WM, Edwards MS, et al. Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. Int J Radiat Oncol Biol Phys 1992;24:599–610.
781. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 1994;74:1827–1834.
782. Prados MD, Wara WM, Edwards MS, et al. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:85–91.
783. Bernhard EJ, Mitchell JB, Deen D, et al. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res 2000;60:86–91.
784. Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro-oncology 2003;5:8–13.
785. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004;58:927–931.
786. Farmer JP, Montes JL, Freeman CR, et al. Brainstem gliomas. A 10-year institutional review. Pediatr Neurosurg 2001;34:206–214.
787. Kun LE. Tumors of the posterior fossa and the spinal canal. In: Halperin EC, Constine LS, Tarbell NJ, et al., eds. Pediatric radiation oncology. Philadelphia: Lippincott, Williams & Wilkins, 2004;107–109.
788. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850–856.
789. Fulton DS, Levin VA, Wara WM, et al. Chemotherapy of pediatric brain-stem tumors. J Neurosurg 1981;54:721–725.
790. Levin VA, Edwards MS, Wara WM, et al. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery 1984;14:679–681.
791. Kretschmar CS, Tarbell NJ, Barnes PD, et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer 1993;72:1404–1413.
792. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol 2002;20:3431–3437.
793. Jenkin RD, Boesel C, Ertel I, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg 1987;66:227–233.
794. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol 1993;15:133–139.
795. Packer RJ. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr Neurosurg 1996;24:211–216.
796. Packer RJ, Cohen BH, Cooney K. Intracranial germ cell tumors. Oncologist 2000;5:312–320.
797. Kretschmar CS. Germ cell tumors of the brain in children: a review of current literature and new advances in therapy. Cancer Invest 1997;15:187–198.
798. Wara WM, Jenkin RD, Evans A, et al. Tumors of the pineal and suprasellar region: Childrens Cancer Study Group treatment results 1960–1975: a report from Childrens Cancer Study Group. Cancer 1979;43:698–701.
799. Edwards MS, Hudgins RJ, Wilson CB, et al. Pineal region tumors in children. J Neurosurg 1988;68:689–697.
800. Jenkin D, Berry M, Chan H, et al. Pineal region germinomas in childhood treatment considerations. Int Radiat Oncol Biol Phys 1990;18:541–545.
801. Abay EO, Laws ER Jr., Grado GL, et al. Pineal tumors in children and adolescents. Treatment by CSF shunting and radiotherapy. J Neurosurg 1981;55:889–895.
802. Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985;63:155–167.
803. D’Andrea AD, Packer RJ, Rorke LB, et al. Pineocytomas of childhood. A reappraisal of natural history and response to therapy. Cancer 1987;59:1353–1357.
804. Disclafani A, Hudgins RJ, Edwards MS, et al. Pineocytomas. Cancer 1989;63:302–304.
805. Gururangan S, Heideman RL, Kovnar EH, et al. Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts. Med Pediatr Oncol 1994;22:417–420.
806. Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997;86:446–455.
807. Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation—a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 1996;14:2908–2915.
808. Hoffman HJ, Otsubo H, Hendrick EB, et al. Intracranial germ-cell tumors in children. J Neurosurg 1991;74:545–551.
809. Jakacki RI, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group. J Clin Oncol 1995;13: 1377–1383.
810. Regis J, Bouillot P, Rouby-Volot F, et al. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. Neurosurgery 1996;39:907–912.
811. Knappe UJ, Bentele K, Horstmann M, et al. Treatment and long-term outcome of pineal nongerminomatous germ cell tumors. Pediatr Neurosurg 1998;28:241–245.
812. Ushio Y, Kochi M, Kuratsu J, et al. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases. J Neurosurg 1999;90:133–137.
813. Yoshida J, Sugita K, Kobayashi T, et al. Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Acta Neurochir (Wien) 1993;120:111–117.
814. Chapman PH, Linggood RM. The management of pineal area tumors: a recent reappraisal. Cancer 1980;46:1253–1257.
815. Paulino AC, Wen BC, Mohideen MN. Controversies in the management of intracranial germinomas. Oncology (Huntingt) 1999;13:513–521; discussion 521–522, 528–533.
816. Sung DI, Harisliadis L, Chang CH. Midline pineal tumors and suprasellar germinomas: highly curable by irradiation. Radiology 1978;128:745–751.
817. Shibamoto Y, Abe M, Yamashita J, et al. Treatment results of intracranial germinoma as a function of the irradiated volume. Int J Radiat Oncol Biol Phys 1988;15:285–290.
818. Linstadt D, Wara WM, Edwards MS, et al. Radiotherapy of primary intracranial germinomas: the case against routine craniospinal irradiation. Int J Radiat Oncol Biol Phys 1988;15:291–297.
819. Shibamoto Y, Sasai K, Oya N, et al. Intracranial germinoma: radiation therapy with tumor volume-based dose selection. Radiology 2001;218:452–456.
820. Aoyama H, Shirato H, Kakuto Y, et al. Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 1998;47:201–205.
821. Calaminus G, Bamberg M, Baranzelli MC, et al. Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics 1994;25:26–32.
822. Merchant TE, Sherwood SH, Mulhern RK, et al. CNS germinoma: disease control and long-term functional outcome for 12 children treated with craniospinal irradiation. Int J Radiat Oncol Biol Phys 2000;46:1171–1176.
823. Bamberg M, Kortmann RD, Calaminus G, et al. Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 1999;17:2585–2592.
824. Baranzelli MC, Patte C, Bouffet E, et al. Nonmetastatic intracranial germinoma: the experience of the French Society of Pediatric Oncology. Cancer 1997;80:1792–1797.
825. Shibamoto Y, Oda Y, Yamashita J, et al. The role of cerebrospinal fluid cytology in radiotherapy planning for intracranial germinoma. Int J Radiat Oncol Biol Phys 1994;29:1089–1094.
826. Bouffet E, Baranzelli MC, Patte C, et al. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d’Oncologie Pediatrique. Br J Cancer 1999;79:1199–1204.
827. Shibamoto Y, Takahashi M, Abe M. Reduction of the radiation dose for intracranial germinoma: a prospective study. Br J Cancer 1994;70:984–989.
828. Hardenbergh PH, Golden J, Billet A, et al. Intracranial germinoma: the case for lower dose radiation therapy. Int J Radiat Oncol Biol Phys 1997;39:419–426.
829. Haas-Kogan DA, Missett BT, Wara WM, et al. Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys 2003;56:511–518.
830. Jereb B, Zupancic N, Petric J. Intracranial germinoma: report of seven cases. Pediatr Hematol Oncol 1990;7:183–188.
831. Patel SR, Buckner JC, Smithson WA, et al. Cisplatin-based chemotherapy in primary central nervous system germ cell tumors. J Neurooncol 1992;12:47–52.
832. Sawamura Y, Shirato H, Ikeda J, et al. Induction chemotherapy followed by reduced-volume radiation therapy for newly diagnosed central nervous system germinoma. J Neurosurg 1998;88:66–72.
833. Paulino AC. Induction chemotherapy and involved-field radiotherapy for intracranial germinoma. J Clin Oncol 2002;20:2911; author reply 2911–2912.
834. Wolden SL, Wara WM, Larson DA, et al. Radiation therapy for primary intracranial germ-cell tumors. Int J Radiat Oncol Biol Phys 1995;32:943–949.
835. Robertson PL, DaRosso RC, Allen JC. Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol 1997;32:71–80.
836. Chamberlain MC, Levin VA. Chemotherapeutic treatment of the diencephalic syndrome. A case report. Cancer 1989;63:1681–1684.
837. Kobayashi T, Yoshida J, Ishiyama J, et al. Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors. An experimental and clinical study. J Neurosurg 1989;70:676–681.
838. Allen JC, Bosl G, Walker R. Chemotherapy trials in recurrent primary intracranial germ cell tumors. J Neurooncol 1985;3:147–152.
839. Schild SE, Haddock MG, Scheithauer BW, et al. Nongerminomatous germ cell tumors of the brain. Int J Radiat Oncol Biol Phys 1996;36:557–563.
840. Allen JC, Kim JH, Packer RJ. Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg 1987;67:65–70.
841. Allen JC, DaRosso RC, Donahue B, et al. A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. Cancer 1994;74:940–944.
842. Pinkerton CR, Broadbent V, Horwich A, et al. ‘JEB’—a carboplatin based regimen for malignant germ cell tumours in children. Br J Cancer 1990;62:257–262.
843. Buckner JC, Peethambaram PP, Smithson WA, et al. Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. J Clin Oncol 1999;17: 933–940.
844. Bryant WP, O’Marcaigh AS, Ledger GA, et al. Aqueous vasopressin infusion during chemotherapy in patients with diabetes insipidus. Cancer 1994;74:2589–2592.
845. Chang TK, Wong TT, Hwang B. Combination chemotherapy with vinblastine, bleomycin, cisplatin, and etoposide (VBPE) in children with primary intracranial germ cell tumors. Med Pediatr Oncol 1995;24:368–372.
846. Kida Y, Kobayashi T, Yoshida J, et al. Chemotherapy with cisplatin for AFP-secreting germ-cell tumors of the central nervous system. J Neurosurg 1986;65:470–475.
847. Itoyama Y, Kochi M, Kuratsu J, et al. Treatment of intracranial nongerminomatous malignant germ cell tumors producing alpha-fetoprotein. Neurosurgery 1995;36:459–464.
848. Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89:547–551.
849. Weiss M, Sutton L, Marcial V, et al. The role of radiation therapy in the management of childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1989;17:1313–1321.
850. Luse SA, Kernohan JW. Squamous-cell nests of the pituitary gland. Cancer 1955;8:623–628.
851. Baskin DS, Wilson CB: Surgical management of craniopharyngiomas. A review of 74 cases. J Neurosurg 1986;65:22–27.
852. Pang D. Surgical management of craniopharyngiomas. New York: Raven Press, 1993.
853. Curtis J, Daneman D, Hoffman HJ, et al. The endocrine outcome after surgical removal of craniopharyngiomas. Pediatr Neurosurg 1994;21[Suppl 1]:24–27.
854. Richmond IL, Wara WM, Wilson CB. Role of radiation therapy in the management of craniopharyngiomas in children. Neurosurgery 1980;6:513–517.
855. Danoff BF, Cowchock FS, Kramer S. Childhood craniopharyngioma: survival, local control, endocrine and neurologic function following radiotherapy. Int J Radiat oncol Biol Phys 1983;9:171–175.
856. Yasargil MG, Curcic M, Kis M, et al. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg 1990;73:3–11.
857. Hoffman HJ, de Silva M, Humphreys RP, et al. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg 1992;76:47–52.
858. Hoffman H, Chuang S, Ehrlich R. The microsurgical removal of craniopharyngiomas in childhood. Concepts Pediatr Neurosurg 1985;6:52.
859. Duff JM, Meyer FB, Ilstrup DM. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000;46:291–305.
860. Bruce DA, Schut L, Rorke LB. Craniopharyngiomas in a capsule? Concepts Pediatr Neurosurg 1981;1:29.
861. Carmel PW. Radical removal of craniopharyngioma: 1971 to 1991. J Neurosurg 1993;72: 351a.
862. Hetelekidis S, Barnes PD, Tao ML, et al. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1993;27:189–195.
863. Manaka S, Teramoto A, Takakura K. The efficacy of radiotherapy for craniopharyngioma. J Neurosurg 1985;62:648–656.
864. Cabezudo JM, Vaquero J, Areitio E, et al. Craniopharyngiomas: a critical approach to treatment. J Neurosurg 1981;55:371–375.
865. Fischer EG, Welch K, Shillito J Jr., et al. Craniopharyngiomas in children. Long-term effects of conservative surgical procedures combined with radiation therapy. J Neurosurg 1990;73:534–540.
866. Lyen KR, Grant DB. Endocrine function, morbidity, and mortality after surgery for craniopharyngioma. Arch Dis Child 1982;57:837–841.
867. Laws ER Jr. Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980;52:661–666.
868. Rajan B, Ashley S, Gorman C, et al. Craniopharyngioma—a long-term results following limited surgery and radiotherapy. Radiother Oncol 1993;26:1–10.
869. Merchant TE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude Children’s Research Hospital experience 1984–2001. Int J Radiat Oncol Biol Phys 2002;53:533–542.
870. Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys 1992;24:611–617.
871. Scott RM, Hetelekidis S, Barnes PD, et al. Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma—a 20-year experience. Pediatr Neurosurg 1994;21[Suppl 1]:75–81.
872. Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 1999;44:255–263.
873. Brada M, Thomas DG. Craniopharyngioma revisited. Int J Radiat Oncol Biol Phys 1993;27:471–475.
874. Varlotto JM, Flickinger JC, Kondziolka D, et al. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002;54:492–499.
875. Kalapurakal JA, Goldman S, Hsieh YC, et al. Clinical outcome in children with craniopharyngioma treated with primary surgery and radiotherapy deferred until relapse. Med Pediatr Oncol 2003;40:214–218.
876. Kalapurakal JA, Goldman S, Hsieh YC, et al. Clinical outcome in children with recurrent craniopharyngioma after primary surgery. Cancer J 2000;6:388–393.
877. Backlund EO. Treatment of craniopharyngiomas: the multimodality approach. Pediatr Neurosurg 1994;21[Suppl 1]:82–89.
878. Lunsford LD, Pollock BE, Kondziolka DS, et al. Stereotactic options in the management of craniopharyngioma. Pediatr Neurosurg 1994;21[Suppl 1]:90–97.
879. Bremer AM, Nguyen TQ, Balsys R. Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report. J Neurooncol 1984;2:47–51.
880. Takahashi H, Nakazawa S, Shimura T. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 1985;62:120–127.
881. Jakacki RI, Cohen BH, Jamison C, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg 2000;92:255–260.
882. Allen J, Wisoff J, Helson L, et al. Choroid plexus carcinoma—responses to chemotherapy alone in newly diagnosed young children. J Neurooncol 1992;12:69–74.
883. Ellenbogen RG, Winston KR, Kupsky WJ. Tumors of the choroid plexus in children. Neurosurgery 1989;25:327–335.
884. Chow E, Reardon DA, Shah AB, et al. Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys 1999;44:249–254.
885. Pierga JY, Kalifa C, Terrier-Lacombe MJ, et al. Carcinoma of the choroid plexus: a pediatric experience. Med Pediatr Oncol 1993;21:480–487.
886. Greenberg ML. Chemotherapy of choroid plexus carcinoma. Childs Nerv Syst 1999;15: 571–577.
887. Carpenter DB, Michelsen WJ, Hays AP. Carcinoma of the choroid plexus. Case report. J Neurosurg 1982;56:722–727.
888. Laurence KM. The biology of choroid plexus papilloma in infancy and childhood. Acta Neurochir (Wien)1979;50:79–90.
889. Tomita T, McLone DG, Flannery AM. Choroid plexus papillomas of neonates, infants and children. Pediatr Neurosci 1988;14:23–30.
890. McGirr SJ, Ebersold MJ, Scheithauer BW, et al. Choroid plexus papillomas: long-term follow-up results in a surgically treated series. J Neurosurg 1988;69:843–849.
891. St Clair SK, Humphreys RP, Pillay PK, et al. Current management of choroid plexus carcinoma in children. Pediatr Neurosurg 1991;17:225–233.
892. Johnson DL. Management of choroid plexus tumors in children. Pediatr Neurosci 1989;15:195–206.
893. Milhorat TH, Hammock MK, Davis DA, et al. Choroid plexus papilloma. I. Proof of cerebrospinal fluid overproduction. Childs Brain 1976;2:273–289.
894. Lowis SP, Pizer BL, Coakham H, et al. Chemotherapy for spinal cord astrocytoma: can natural history be modified? Childs Nerv Syst 1998;14:317–321.
895. Lonjon M, Goh KY, Epstein FJ. Intramedullary spinal cord ependymomas in children: treatment, results and follow-up. Pediatr Neurosurg 1998;29:178–183.
896. Allen JC, Aviner S, Yates AJ, et al. Treatment of high-grade spinal cord astrocytoma of childhood with “8-in-1” chemotherapy and radiotherapy: a pilot study of CCG-945. Children’s Cancer Group. J Neurosurg 1998;88:215–220.
897. Mottl H, Koutecky J. Treatment of spinal cord tumors in children. Med Pediatr oncol 1997;29:293–295.
898. Bouffet E, Pierre-Kahn A, Marchal JC, et al. Prognostic factors in pediatric spinal cord astrocytoma. Cancer 1998;83:2391–2399.
899. Peschel RE, Kapp DS, Cardinale F, et al. Ependymomas of the spinal cord. Int J Radiat Oncol Biol Phys 1983;9:1093–1096.
900. Reimer R, Onofrio BM. Astrocytomas of the spinal cord in children and adolescents. J Neurosurg 1985;63:669–675.
901. Hardison HH, Packer RJ, Rorke LB, et al. Outcome of children with primary intramedullary spinal cord tumors. Childs Nerv Syst 1987;3:89–92.
902. Cohen AR, Wisoff JH, Allen JC, et al. Malignant astrocytomas of the spinal cord. J Neurosurg 1989;70:50–54.
903. Cooper PR. Outcome after operative treatment of intramedullary spinal cord tumors in adults: intermediate and long-term results in 51 patients. Neurosurgery 1989;25:855–859.
904. Epstein F, Epstein N. Surgical treatment of spinal cord astrocytomas of childhood. A series of 19 patients. J Neurosurg 1982;57:685–689.
905. O’Sullivan C, Jenkin RD, Doherty MA, et al. Spinal cord tumors in children: long-term results of combined surgical and radiation treatment. J Neurosurg 1994;81:507–512.
906. Muszynski CA, Constantini S, Epstein FJ. Intraspinal intramedullary neoplasms. In: Albright LA, Pollack IF, Adelson PD, eds. Principles and practice of pediatric neurosurgery. New York: Thieme, 1999:697–709.
907. Cristante L, Herrmann HD. Surgical management of intramedullary spinal cord tumors: functional outcome and sources of morbidity. Neurosurgery 1994;35:69–74.
908. Albright AL. Pediatric intramedullary spinal cord tumors. Childs Nerv Syst 1999;15:436–438.
909. Linstadt DE, Wara WM, Leibel SA, et al. Postoperative radiotherapy of primary spinal cord tumors. Int J Radiat Oncol Biol Phys 1989;16:1397–1403.
910. Chun HC, Schmidt-Ullrich RK, Wolfson A, et al. External beam radiotherapy for primary spinal cord tumors. J Neurooncol 1990;9:211–217.
911. Merchant TE, Nguyen D, Thompson SJ, et al. High-grade pediatric spinal cord tumors. Pediatr Neurosurg 1999;30:1–5.
912. Doireau V, Grill J, Zerah M, et al. Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). Br J Cancer 1999;81:835–840.
913. Linet MS, Ries LA, Smith MA, et al. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999;91:1051–1058.
914. Mulhern RK, Horowitz ME, Kovnar EH, et al. Neurodevelopmental status of infants and young children treated for brain tumors with preirradiation chemotherapy. J Clin Oncol 1989;7:1660–1666.
915. Kao GD, Goldwein JW, Schultz DJ, et al. The impact of perioperative factors on subsequent intelligence quotient deficits in children treated for medulloblastoma/posterior fossa primitive neuroectodermal tumors. Cancer 1994;74:965–971.
916. Duffner PK, Cohen ME. Long-term consequences of CNS treatment for childhood cancer, Part II: Clinical consequences. Pediatr Neurol 1991;7:237–242.
917. Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 1989;70:707–713.
918. Anderson VA, Godber T, Smibert E, et al. Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer 2000;82: 255–262.
919. Johnson DL, McCabe MA, Nicholson HS, et al. Quality of long-term survival in young children with medulloblastoma. J Neurosurg 1994;80:1004–1010.
920. Jannoun L, Bloom HJ. Long-term psychological effects in children treated for intracranial tumors. Int J Radiat Oncol Biol Phys 1990;18:747–753.
921. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390–1396.
922. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 2001;19: 2302–2308.
923. Palmer SL, Gajjar A, Reddick WE, et al. Predicting intellectual outcome among children treated with 35–40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 2003;17:548–555.
924. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, et al. Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst 1990;6:60–65.
925. Dennis M, Spiegler BJ, Hoffman HJ, et al. Brain tumors in children and adolescents—I. Effects on working, associative and serial-order memory of IQ, age at tumor onset and age of tumor. Neuropsychologia 1991;29:813–827.
926. Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001;19: 1802–1808.
927. Shalet SM, Gibson B, Swindell R, et al. Effect of spinal irradiation on growth. Arch Dis Child 1987;62:461–464.
928. Duffner PK, Cohen ME, Thomas PR, et al. The long-term effects of cranial irradiation on the central nervous system. Cancer 1985;56:1841–1846.
929. Olshan JS, Gubernick J, Packer RJ, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013–2017.
930. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001;19:480–487.
931. Moshang T Jr., Rundle AC, Graves DA, et al. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr 1996;128:S4–S7.
932. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85:4444–4449.
933. Livesey EA, Hindmarsh PC, Brook CG, et al. Endocrine disorders following treatment of childhood brain tumours. Br J Cancer 1990;61:622–625.
934. Belza MG, Donaldson SS, Steinberg GK, et al. Medulloblastoma: freedom from relapse longer than 8 years—a therapeutic cure? J Neurosurg 1991;75:575–582.
935. Kramer ED, Vezina LG, Packer RJ, et al. Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children’s Cancer Group. Pediatr Neurosurg 1994;20:254–262.
936. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994;330:892–895.
937. Shaw DW, Geyer JR, Berger MS, et al. Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma. J Clin Oncol 1997;15:1811–1813.
938. Duffner PK, Cohen ME, Thomas P. Late effects of treatment on the intelligence of children with posterior fossa tumors. Cancer 1983;51:233–237.
939. Jenkin D, Danjoux C, Greenberg M. Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol 1998;31:506–511.
940. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. Br J Cancer 1997;76:1–14.
941. Lasser DM, DeVivo DC, Garvin J, et al. Turcot’s syndrome: evidence for linkage to the adenomatous polyposis coli (APC) locus. Neurology 1994;44:1083–1086.
942. Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001;19:1288–1296.